

PATENT COOPERATION T ATY

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Assistant Commissioner for Patents
United States Patent and Trademark
Office
Box PCT
Washington, D.C.20231
ÉTATS-UNIS D'AMÉRIQUE

in its capacity as elected Office

Date of mailing (day/month/year) 18 November 1999 (18.11.99)	
International application No. PCT/EP99/02722	Applicant's or agent's file reference 16363PC RUU
International filing date (day/month/year) 22 April 1999 (22.04.99)	Priority date (day/month/year) 24 April 1998 (24.04.98)
Applicant DIU-HERCEND, Anita et al	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:
06 October 1999 (06.10.99)

☐ in a notice effecting later election filed with the International Bureau on:

2. The election ☒ was
☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	Authorized officer A. Karkachi Telephone No.: (41-22) 338.83.38
---	---

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference 16363PC RUU	FOR FURTHER ACTION see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. PCT/EP 99/ 02722	International filing date (day/month/year) 22/04/1999	(Earliest) Priority Date (day/month/year) 24/04/1998
Applicant HOECHST MARION ROUSSEL		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 6 sheets.

☐ It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the report

- a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

- b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :

☒ contained in the international application in written form.

☒ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☐ furnished subsequently to this Authority in computer readable form.

☒ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☒ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☐ **Certain claims were found unsearchable** (See Box I).

3. ☒ **Unity of invention is lacking** (see Box II).

4. With regard to the **title**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established by this Authority to read as follows:

5. With regard to the **abstract**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No.

☐ as suggested by the applicant.

☐ because the applicant failed to suggest a figure.

☐ because this figure better characterizes the invention.

☐ None of the figures.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP 99/02722

Box I Observation where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

see FURTHER INFORMATION sheet, subject 1.

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

1. Claims: 1-12 (partial)

INVENTION 1:

Method for the screening of antimycotic substances wherein an essential gene from mycetes, or a functionally similar mycete gene, or the corresponding encoded protein, is used as a target, and wherein the essential gene is YML114c.

2. Claims: 1-12 (partial)

INVENTION 2 to INVENTION 90:

Method for the screening of antimycotic substances wherein an essential gene from mycetes, or a functionally similar mycete gene, or the corresponding encoded protein, is used as a target, and wherein the essential gene is YLR186w, YLR215c, or YLR222c, ..., or YPR144c, or YPR169w.

Invention 2 refers to gene YLR186w,
invention 3 refers to gene YLR215c,

...
invention 89 refers to gene YPR144c, and
invention 90 refers to gene YPR169w.

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP 99/02722

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C12Q1/68 C12Q1/18

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 97 36925 A (SCRIPTGEN PHARM INC ; HARVARD COLLEGE (US)) 9 October 1997 see the whole document ---	1-7
X	EP 0 816 511 A (HANS KNOELL INST FUER NATURSTO) 7 January 1998 see the whole document ---	1-7
X	US 5 614 377 A (BULAWA CHRISTINE E) 25 March 1997 see the whole document ---	1-4, 7, 9, 10 8
Y		
X	EP 0 626 453 A (AMERICAN CYANAMID CO) 30 November 1994 see the whole document ---	1-4
	--- -/-	

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

19 October 1999

Date of mailing of the international search report

20.01.2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tlx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Knehr, M

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP 99/02722

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 554 042 A (DOWELANCO) 4 August 1993 see abstract see page 2, column 1, line 26 - page 3, column 1, line 26; claims 1,2,4-9 ---	1-4
X. Y	WO 95 11969 A (RIBOGENE INC) 4 May 1995 see the whole document line 26; claims 1,2,4-9 ---	1-4 5-8,11, 12
X	SIKORSKI J A ET AL.: "Selective peptidic and peptidomimetic inhibitors of Candida albicans myristoylCoA: Protein N-myristoyltransferase: A new approach to antifungal therapy" PEPTIDE SCIENCE, vol. 43, no. 1, 1997, XP002119360 see the whole document line 26; claims 1,2,4-9 ---	1,3,4,7
X	EP 0 188 677 A (PHILLIPS PETROLEUM CO) 30 July 1986 see abstract; claims 1-4 ---	1,8
X Y	EP 0 626 454 A (AMERICAN CYANAMID CO) 30 November 1994 see abstract; claims 1-4 see page 3, line 24 - line 57 see page 6, line 1 - line 4; claims 1-5,7,9; table 1 ---	1-4 5-9,11, 12
Y	EP 0 644 262 A (TAKARA SHUZO CO) 22 March 1995 see abstract line 4; claims 1-5,7,9; table 1 see page 2, line 1 - page 3, line 44; table 1 see page 4, line 17 - page 5, line 24; table 1 see page 6, line 5 - line 31; table 1 see page 9, line 35 - line 43; claim 15; example 2; table 1 ---	1-4,6-9, 11,12
Y	KURTZ M B AND DOUGLAS C M: "Lipopeptide inhibitors of fungal glucan synthase" JOURNAL OF MEDICAL AND VETERINARY MYCOLOGY, vol. 2, no. 35, 1 January 1997, page 79 86 XP002078810 see abstract line 43; claim 15; example 2; table 1 see page 79, column 1, paragraph 1 - page 81, column 2, paragraph 1; figures 1,2; table 1 ---	1-4,6,7

-/--

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP 99/02722

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 96 08264 A (CERES TECHNOLOGIES INC) 21 March 1996 see the whole document paragraph 1; figures 1,2; table 1 ---	
P,X	WO 98 44135 A (HEGEMANN JOHANNES ;ZIMMERMANN FRIEDRICH KARL (DE); HINNEN ALBERT () 8 October 1998 see the whole document paragraph 1; figures 1,2; table 1 -----	1-5,7,8, 11,12

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 99/02722

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9736925	A	09-10-1997	CA 2250129 A EP 0904289 A	09-10-1997 31-03-1999
EP 0816511	A	07-01-1998	NONE	
US 5614377	A	25-03-1997	WO 9523235 A	31-08-1995
EP 0626453	A	30-11-1994	AT 186747 T DE 69421641 D	15-12-1999 23-12-1999
EP 0554042	A	04-08-1993	US 5976848 A DE 69324831 D DE 69324831 T JP 6113889 A	02-11-1999 17-06-1999 09-09-1999 26-04-1994
WO 9511969	A	04-05-1995	AU 686685 B AU 8088494 A EP 0725818 A JP 9504176 T US 5641627 A US 5871923 A	12-02-1998 22-05-1995 14-08-1996 28-04-1997 24-06-1997 16-02-1999
EP 0188677	A	30-07-1986	US 4885242 A AU 571748 B AU 4875185 A DK 496285 A ES 548305 A FI 854144 A GR 852608 A JP 7163354 A JP 2617443 B JP 61108391 A JP 2710610 B JP 9168388 A NO 854333 A PT 81401 A,B	05-12-1989 21-04-1988 12-06-1986 01-05-1986 16-07-1986 01-05-1986 04-03-1986 27-06-1995 04-06-1997 27-05-1986 10-02-1998 30-06-1997 02-05-1986 01-11-1985
EP 0626454	A	30-11-1994	US 5418144 A	23-05-1995
EP 0644262	A	22-03-1995	AU 677387 B AU 6312994 A CA 2124034 A JP 7313172 A	24-04-1997 01-12-1994 25-11-1994 05-12-1995
WO 9608264	A	21-03-1996	US 5602097 A AU 3589895 A CA 2199941 A EP 0783316 A US 5885782 A	11-02-1997 29-03-1996 21-03-1996 16-07-1997 23-03-1999
WO 9844135	A	08-10-1998	DE 19713572 A AU 7213898 A	22-10-1998 22-10-1998

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 16363PC RUU	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No PCT/EP99/02722	International filing date (<i>day/month/year</i>) 22/04/1999	Priority date (<i>day/month/year</i>) 24/04/1998
International Patent Classification (IPC) or national classification and IPC C12Q1/68		
Applicant HOECHST MARION ROUSSEL et al.		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.


2. This REPORT consists of a total of 7 sheets, including this cover sheet.

- ☐ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☒ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☒ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☒ Certain observations on the international application

Date of submission of the demand 06/10/1999	Date of completion of this report 19.07.2000
Name and mailing address of the international preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer Linker, W Telephone No. +49 89 2399 8703



**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/EP99/02722

I. Basis of the report

1. This report has been drawn on the basis of (*substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments.*):

Description, pages:

1-41 as originally filed

Claims, No.:

1-12 as originally filed

2. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
☐ the claims, Nos.:
☐ the drawings, sheets:

3. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

4. Additional observations, if necessary:

III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:

- ☐ the entire international application.
☒ claims Nos. 1-12 (part).

because:

- ☐ the said international application, or the said claims Nos. relate to the following subject matter which does not require an international preliminary examination (*specify*):

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/EP99/02722

- ☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):
- ☐ the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.
- ☒ no international search report has been established for the said claims Nos. 1-12 (part).

IV. Lack of unity of invention

1. In response to the invitation to restrict or pay additional fees the applicant has:

- ☐ restricted the claims.
- ☐ paid additional fees.
- ☐ paid additional fees under protest.
- ☐ neither restricted nor paid additional fees.

2. ☒ This Authority found that the requirement of unity of invention is not complied and chose, according to Rule 68.1, not to invite the applicant to restrict or pay additional fees.

3. This Authority considers that the requirement of unity of invention in accordance with Rules 13.1, 13.2 and 13.3 is

- ☐ complied with.
- ☒ not complied with for the following reasons:

see separate sheet

4. Consequently, the following parts of the international application were the subject of international preliminary examination in establishing this report:

- ☐ all parts.
- ☒ the parts relating to claims Nos. 1-12 (part).

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/EP99/02722

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes:	Claims	1-12
	No:	Claims	
Inventive step (IS)	Yes:	Claims	
	No:	Claims	1-12
Industrial applicability (IA)	Yes:	Claims	1-12
	No:	Claims	

2. Citations and explanations

see separate sheet

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

see separate sheet

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/EP99/02722

Re Item III

Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

The international search report was restricted to this part of the application which relates to a method for screening of antimycotic substances wherein an essential gene from mycetes, or a functionally similar mycete gene, or a corresponding encoded protein is used as a target, and wherein the essential gene is YML114c.

Re Item IV

Lack of unity of invention

The objection indicated on form 210 dated 08.11.99 submitted by the International Searching Authority is confirmed. Each of the essential mycetes genes listed in claim 1 as YML114c, YLR186w, YLR215c, ..., YPR144c, and YPR169w represent an independent solution of the underlying problem which could be regarded as to provide further essential mycete genes/proteins suitable as targets in a method for screening of antimycotic/fungicide substances

Re Item V

Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

Reference is made to the following documents:

- D1: WO 97 36925 A (SCRIPTGEN PHARM INC ;HARVARD COLLEGE (US)) 9 October 1997
- D2: EP-A-0 816 511 (HANS KNOELL INST FUER NATURSTO) 7 January 1998
- D3: US-A-5 614 377 (BULAWA CHRISTINE E) 25 March 1997
- D4: EP-A-0 626 453 (AMERICAN CYANAMID CO) 30 November 1994
- D5: EP-A-0 554 042 (DOWELANCO) 4 August 1993
- D6: WO 95 11969 A (RIBOGENE INC) 4 May 1995

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/EP99/02722

Document D1 discloses methods for screening for inhibitors of *C. albicans* growth by targeting the TATA-binding protein.

Document D2 discloses a method of finding novel antifungal drugs which inhibit essential yeast genes (i.e. acetyl-CoA carboxylase) without knowledge of the biological function of the targets.

Document D3 discloses a method for identifying inhibitors of fungal pathogenicity relying on the use of defined genes and mutant strains of *Saccharomyces cerevisiae*, specifically referring to the CSD2 gene from *C. albicans* which is a homolog of the corresponding *Saccharomyces cerevisiae* gene CSD2.

Document D4 discloses a method for screening for potential fungicides that inhibit cytochrome P450 reductase or reductase related enzymes or proteins involved in its biosynthesis.

Document D5 discloses a method for screening fungicides by testing candidate compounds in a dihydroorotate dehydrogenase (DHOD) inhibition assay.

Document D6 discloses screening methods for identification of antimycotic agents active in mycotic cell translation, based on a reporter gene system associated with a CN4type gene from *Saccharomyces cerevisiae*.

The subject-matter of claim 1 is distinguished from the cited prior art in that the gene YML114c is used as a target. However, as the gene as such was already known in the prior art and methods for screening of antimycotic substances based upon the functional inhibition/targeting of the expression of essential mycetes genes, or the corresponding encoded proteins, was also known in the art, see documents D1-D6, moreover, no surprising or unforeseeable effects are apparent from the application with respect to YML114c target gene, the subject-matter of claim 1 lacks an inventive step and does not fulfil the requirements of Article 33(3) PCT.

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/EP99/02722

Dependent claims 2-12 do not appear to contain any additional feature which could be regarded as inventive.

Re Item VI

Certain documents cited

Certain published documents (Rule 70.10)

<u>Application No</u> <u>Patent No</u>	<u>Publication date</u> <u>(day/month/year)</u>	<u>Filing date</u> <u>(day/month/year)</u>	<u>Priority date (valid claim)</u> <u>(day/month/year)</u>
WO98/44135	08.10.98	02.04.98	02.04.97

Re Item VIII

Certain observations on the international application

The wording "functionally similar gene" used in claims 1, 6, 7, 8 and 10 is not clear, as no function of YML114c was defined, furthermore, the wording "the corresponding encoded protein" used in claim 1 is not clear, as no particular protein of YML114c was defined in the application. The aforementioned claims do not fulfil the requirements of Article 6 PCT.

25 JUL 2000

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 16363PC RUU	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416) FOR FURTHER ACTION	
International application No. PCT/EP99/02722	International filing date (day/month/year) 22/04/1999	Priority date (day/month/year) 24/04/1998
International Patent Classification (IPC) or national classification and IPC C12Q1/68		
Applicant HOECHST MARION ROUSSEL et al.		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.



2. This REPORT consists of a total of 7 sheets, including this cover sheet.

- ☐ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☒ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☒ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☒ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☒ Certain observations on the international application

Date of submission of the demand 06/10/1999	Date of completion of this report 19.07.2000
Name and mailing address of the international preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer Linker, W Telephone No. +49 89 2399 8703 

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/EP99/02722

I. Basis of the report

1. This report has been drawn on the basis of (*substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments.*):

Description, pages:

1-41 as originally filed

Claims, No.:

1-12 as originally filed

2. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
☐ the claims, Nos.:
☐ the drawings, sheets:

3. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

4. Additional observations, if necessary:

III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:

- ☐ the entire international application.
☒ claims Nos. 1-12 (part).

because:

- ☐ the said international application, or the said claims Nos. relate to the following subject matter which does not require an international preliminary examination (*specify*):

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/EP99/02722

- ☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):
- ☐ the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.
- ☒ no international search report has been established for the said claims Nos. 1-12 (part).

IV. Lack of unity of invention

1. In response to the invitation to restrict or pay additional fees the applicant has:

- ☐ restricted the claims.
- ☐ paid additional fees.
- ☐ paid additional fees under protest.
- ☐ neither restricted nor paid additional fees.

2. ☒ This Authority found that the requirement of unity of invention is not complied and chose, according to Rule 68.1, not to invite the applicant to restrict or pay additional fees.

3. This Authority considers that the requirement of unity of invention in accordance with Rules 13.1, 13.2 and 13.3 is

- ☐ complied with.
- ☒ not complied with for the following reasons:

see separate sheet

4. Consequently, the following parts of the international application were the subject of international preliminary examination in establishing this report:

- ☐ all parts.
- ☒ the parts relating to claims Nos. 1-12 (part).

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/EP99/02722

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes:	Claims 1-12
	No:	Claims
Inventive step (IS)	Yes:	Claims
	No:	Claims 1-12
Industrial applicability (IA)	Yes:	Claims 1-12
	No:	Claims

2. Citations and explanations

see separate sheet

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

see separate sheet

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/EP99/02722

Re Item III

Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

The international search report was restricted to this part of the application which relates to a method for screening of antimycotic substances wherein an essential gene from mycetes, or a functionally similar mycete gene, or a corresponding encoded protein is used as a target, and wherein the essential gene is YML114c.

Re Item IV

Lack of unity of invention

The objection indicated on form 210 dated 08.11.99 submitted by the International Searching Authority is confirmed. Each of the essential mycetes genes listed in claim 1 as YML114c, YLR186w, YLR215c, ..., YPR144c, and YPR169w represent an independent solution of the underlying problem which could be regarded as to provide further essential mycete genes/proteins suitable as targets in a method for screening of antimycotic/fungicide substances

Re Item V

Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

Reference is made to the following documents:

- D1: WO 97 36925 A (SCRIPTGEN PHARM INC ;HARVARD COLLEGE (US)) 9 October 1997
- D2: EP-A-0 816 511 (HANS KNOELL INST FUER NATURSTO) 7 January 1998
- D3: US-A-5 614 377 (BULAWA CHRISTINE E) 25 March 1997
- D4: EP-A-0 626 453 (AMERICAN CYANAMID CO) 30 November 1994
- D5: EP-A-0 554 042 (DOWELANCO) 4 August 1993
- D6: WO 95 11969 A (RIBOGENE INC) 4 May 1995

:

Document D1 discloses methods for screening for inhibitors of *C. albicans* growth by targeting the TATA-binding protein.

Document D2 discloses a method of finding novel antifungal drugs which inhibit essential yeast genes (i.e. acetyl-CoA carboxylase) without knowledge of the biological function of the targets.

Document D3 discloses a method for identifying inhibitors of fungal pathogenicity relying on the use of defined genes and mutant strains of *Saccharomyces cerevisiae*, specifically referring to the CSD2 gene from *C. albicans* which is a homolog of the corresponding *Saccharomyces cerevisiae* gene CSD2.

Document D4 discloses a method for screening for potential fungicides that inhibit cytochrome P450 reductase or reductase related enzymes or proteins involved in its biosynthesis.

Document D5 discloses a method for screening fungicides by testing candidate compounds in a dihydroorotate dehydrogenase (DHOD) inhibition assay.

Document D6 discloses screening methods for identification of antimycotic agents active in mycotic cell translation, based on a reporter gene system associated with a CN4type gene from *Saccharomyces cerevisiae*.

The subject-matter of claim 1 is distinguished from the cited prior art in that the gene YML114c is used as a target. However, as the gene as such was already known in the prior art and methods for screening of antimycotic substances based upon the functional inhibition/targeting of the expression of essential mycetes genes, or the corresponding encoded proteins, was also known in the art, see documents D1-D6, moreover, no surprising or unforeseeable effects are apparent from the application with respect to YML114c target gene, the subject-matter of claim 1 lacks an inventive step and does not fulfil the requirements of Article 33(3) PCT.

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/EP99/02722

Dependent claims 2-12 do not appear to contain any additional feature which could be regarded as inventive.

Re Item VI

Certain documents cited

Certain published documents (Rule 70.10)

<u>Application No</u> <u>Patent No</u>	<u>Publication date</u> <u>(day/month/year)</u>	<u>Filing date</u> <u>(day/month/year)</u>	<u>Priority date (valid claim)</u> <u>(day/month/year)</u>
WO98/44135	08.10.98	02.04.98	02.04.97

Re Item VIII

Certain observations on the international application

The wording "functionally similar gene" used in claims 1, 6, 7, 8 and 10 is not clear, as no function of YML114c was defined, furthermore, the wording "the corresponding encoded protein" used in claim 1 is not clear, as no particular protein of YML114c was defined in the application. The aforementioned claims do not fulfil the requirements of Article 6 PCT.

M.H

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12Q 1/68, 1/18		A3	(11) International Publication Number: WO 99/55907
		(43) International Publication Date: 4 November 1999 (04.11.99)	
(21) International Application Number: PCT/EP99/02722 (22) International Filing Date: 22 April 1999 (22.04.99) (30) Priority Data: 98401007.4 24 April 1998 (24.04.98) EP 98402254.1 11 September 1998 (11.09.98) EP (71) Applicant (for all designated States except US): HOECHST MARION ROUSSEL [FR/FR]; 1, terrasse Bellini, F-92800 Puteaux (FR). (72) Inventors; and (75) Inventors/Applicants (for US only): DIU-HERCEND, Anita [FR/FR]; 39, rue Gabrielle, F-94220 Charenton le Pont (FR), ENTIAN, Karl-Dieter [DE/DE]; Oberurseler Strasse 43, D-61440 Oberursel (DE), KOETTER, Peter [DE/DE]; Industriestrasse 3A, D-61440 Oberursel (DE). (74) Agents: POCHART, François et al.; Cabinet Hirsch-Desrousseaux-Pochart, 34, rue de Bassano, F-75008 Paris (FR).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> (88) Date of publication of the international search report: 16 March 2000 (16.03.00)	
(54) Title: METHOD FOR SCREENING ANTIMYCOTIC SUBSTANCES USING ESSENTIAL GENES FROM S. CEREVISIAE			
(57) Abstract			
<p>The present invention concerns a method for the screening of antimycotic substances wherein an essential gene from mycetes or a functionally similar mycete gene, or the corresponding encoded protein, is used as target and wherein the essential gene is selected from the group consisting in YML114c, YLR186w, YLR215c, YLR222c, YLR243w, YLR272c, YLR275w, YLR276c, YLR317w, YLR359w, YLR373c, YLR424w, YLR437c, YLR440c, YML023c, YML049c, YML077w, YML093w, YML127w, YMR032w, YMR093w, YMR131c, YMR185w, YMR212c, YMR213w, YMR218c, YMR281w, YMR288w, YMR290c, YMR211w, YMR049c, YMR134w, YDR196c, YDR299w, YDR365c, YDR396w, YDR407c, YDR416w, YDR449c, YDR472w, YDR499w, YDR141c, YDR324c, YDR325w, YDR398w, YDR246w, YDR236c, YDR361c, YDR367w, YDR339c, YDR413c, YDR429c, YDR468c, YDR489w, YDR527w, YDR288w, YDR201w, YDR434w, YDR181c, YDR531w, YPL126w, YPL093w, YPL063w, YPL024w, YPL020c, YPL012w, YPL007c, YPL233w, YPL146c, YIL091c, YIL083c, YIL019w, YIL109c, YIL104c, YFL024c, YFR003c, YFR027w, YFR042w, YIR010w, YIR015w, YPR048w, YPR072w, YPR082c, YPR085c, YPR105c, YPR112c, YPR137w, YPR143w, YPR144c and YPR169w.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Larvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 99/02722

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12Q1/68 C12Q1/18

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 97 36925 A (SCRIPTGEN PHARM INC ;HARVARD COLLEGE (US)) 9 October 1997 see the whole document ---	1-7
X	EP 0 816 511 A (HANS KNOELL INST FUER NATURSTO) 7 January 1998 see the whole document ---	1-7
X	US 5 614 377 A (BULAWA CHRISTINE E) 25 March 1997 see the whole document ---	1-4,7,9, 10 8
Y		
X	EP 0 626 453 A (AMERICAN CYANAMID CO) 30 November 1994 see the whole document ---	1-4

	-/--	

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the international search

19 October 1999

Date of mailing of the international search report

20.01.2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Knehr, M

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 554 042 A (DOWELANCO) 4 August 1993 see abstract see page 2, column 1, line 26 - page 3, column 1, line 26; claims 1,2,4-9 ---	1-4
X Y	WO 95 11969 A (RIBOGENE INC) 4 May 1995 see the whole document line 26; claims 1,2,4-9 ---	1-4 5-8,11, 12
X	SIKORSKI J A ET AL.: "Selective peptidic and peptidomimetic inhibitors of Candida albicans myristoylCoA: Protein N-myristoyltransferase: A new approach to antifungal therapy" PEPTIDE SCIENCE, vol. 43, no. 1, 1997, XP002119360 see the whole document line 26; claims 1,2,4-9 ---	1,3,4,7
X	EP 0 188 677 A (PHILLIPS PETROLEUM CO) 30 July 1986 see abstract; claims 1-4 ---	1,8
X Y	EP 0 626 454 A (AMERICAN CYANAMID CO) 30 November 1994 see abstract; claims 1-4 see page 3, line 24 - line 57 see page 6, line 1 - line 4; claims 1-5,7,9; table 1 ---	1-4 5-9,11, 12
Y	EP 0 644 262 A (TAKARA SHUZO CO) 22 March 1995 see abstract line 4; claims 1-5,7,9; table 1 see page 2, line 1 - page 3, line 44; table 1 see page 4, line 17 - page 5, line 24; table 1 see page 6, line 5 - line 31; table 1 see page 9, line 35 - line 43; claim 15; example 2; table 1 ---	1-4,6-9, 11,12
Y	KURTZ M B AND DOUGLAS C M: "Lipopeptide inhibitors of fungal glucan synthase" JOURNAL OF MEDICAL AND VETERINARY MYCOLOGY, vol. 2, no. 35, 1 January 1997, page 79 86 XP002078810 see abstract line 43; claim 15; example 2; table 1 see page 79, column 1, paragraph 1 - page 81, column 2, paragraph 1; figures 1,2; table 1 ---	1-4,6,7

	-/--	

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 96 08264 A (CERES TECHNOLOGIES INC) 21 March 1996 see the whole document paragraph 1; figures 1,2; table 1 ---	
P,X	WO 98 44135 A (HEGEMANN JOHANNES ;ZIMMERMANN FRIEDRICH KARL (DE); HINNEN ALBERT () 8 October 1998 see the whole document paragraph 1; figures 1,2; table 1 -----	1-5,7,8, 11,12

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP 99/02722

Box I Observation where certain claim were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

B x II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

see FURTHER INFORMATION sheet, subject 1.

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

1. Claims: 1-12 (partial)

INVENTION 1:

Method for the screening of antimycotic substances wherein an essential gene from mycetes, or a functionally similar mycete gene, or the corresponding encoded protein, is used as a target, and wherein the essential gene is YML114c.

2. Claims: 1-12 (partial)

INVENTION 2 to INVENTION 90:

Method for the screening of antimycotic substances wherein an essential gene from mycetes, or a functionally similar mycete gene, or the corresponding encoded protein, is used as a target, and wherein the essential gene is YLR186w, YLR215c, or YLR222c, ..., or YPR144c, or YPR169w.

Invention 2 refers to gene YLR186w,
invention 3 refers to gene YLR215c,

...
invention 89 refers to gene YPR144c, and
invention 90 refers to gene YPR169w.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 99/02722

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9736925	A	09-10-1997	CA 2250129 A EP 0904289 A	09-10-1997 31-03-1999
EP 0816511	A	07-01-1998	NONE	
US 5614377	A	25-03-1997	WO 9523235 A	31-08-1995
EP 0626453	A	30-11-1994	AT 186747 T DE 69421641 D	15-12-1999 23-12-1999
EP 0554042	A	04-08-1993	US 5976848 A DE 69324831 D DE 69324831 T JP 6113889 A	02-11-1999 17-06-1999 09-09-1999 26-04-1994
WO 9511969	A	04-05-1995	AU 686685 B AU 8088494 A EP 0725818 A JP 9504176 T US 5641627 A US 5871923 A	12-02-1998 22-05-1995 14-08-1996 28-04-1997 24-06-1997 16-02-1999
EP 0188677	A	30-07-1986	US 4885242 A AU 571748 B AU 4875185 A DK 496285 A ES 548305 A FI 854144 A GR 852608 A JP 7163354 A JP 2617443 B JP 61108391 A JP 2710610 B JP 9168388 A NO 854333 A PT 81401 A,B	05-12-1989 21-04-1988 12-06-1986 01-05-1986 16-07-1986 01-05-1986 04-03-1986 27-06-1995 04-06-1997 27-05-1986 10-02-1998 30-06-1997 02-05-1986 01-11-1985
EP 0626454	A	30-11-1994	US 5418144 A	23-05-1995
EP 0644262	A	22-03-1995	AU 677387 B AU 6312994 A CA 2124034 A JP 7313172 A	24-04-1997 01-12-1994 25-11-1994 05-12-1995
WO 9608264	A	21-03-1996	US 5602097 A AU 3589895 A CA 2199941 A EP 0783316 A US 5885782 A	11-02-1997 29-03-1996 21-03-1996 16-07-1997 23-03-1999
WO 9844135	A	08-10-1998	DE 19713572 A AU 7213898 A	22-10-1998 22-10-1998

PCT

REQUEST

The undersigned requests that the present international application be processed according to the Patent Cooperation Treaty.

For receiving Office use only

International Application No.

International Filing Date

Name of receiving Office and "PCT International Application"

Applicant's or agent's file reference
(if desired) (12 characters maximum)

16363PC RUU

Box No. I TITLE OF INVENTION

METHOD FOR SCREENING ANTIMYCOTIC SUBSTANCES USING ESSENTIAL GENES FROM S. CEREVISIAE

Box No. II APPLICANT

Name and address: (Family name followed by given name, for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below)

HOECHST MARION ROUSSEL
1 Terrasse Bellini
92800 PUTEAUX

☐ This person is also inventor.

Telephone No

Facsimile No

Teleprinter No

State (that is, country) of nationality:

FRANCE

State (that is, country) of residence:

FRANCE

This person is applicant for the purposes of:

☐

all designated States

☒

all designated States except the United States of America

☐

the United States of America only

☐

the States indicated in the Supplemental Box

Box No. III FURTHER APPLICANT(S) AND/OR (FURTHER) INVENTOR(S)

Name and address: (Family name followed by given name, for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below)

DIU-HERCEND Anita
39 RUE Gabrielle
94220 CHARENTON LE PONT

This person is:

☐ applicant only

☒ applicant and inventor

☐ inventor only (If this check-box is marked, do not fill in below)

State (that is, country) of nationality:

FRANCE

State (that is, country) of residence:

FRANCE

This person is applicant for the purposes of:

☐

all designated States

☐

all designated States except the United States of America

☒

the United States of America only

☐

the States indicated in the Supplemental Box

☒ Further applicants and/or (further) inventors are indicated on a continuation sheet.

Box No. IV AGENT OR COMMON REPRESENTATIVE; OR ADDRESS FOR CORRESPONDENCE

The person identified below is hereby/has been appointed to act on behalf of the applicant(s) before the competent International Authorities as:

☒

agent

☐

common representative

Name and address: (Family name followed by given name, for a legal entity, full official designation. The address must include postal code and name of country)

POCHART François
CABINET HIRSCH-DESROUSSEAUX-POCHART
34 rue de Bassano
75008 PARIS

Telephone No

01 53 23 92 12

Facsimile No

01 47 23 93 75

Teleprinter No

☒ Address for correspondence: Mark this check-box where no agent or common representative is/has been appointed and the space above is used instead to indicate a special address to which correspondence should be sent.

Continuation of Box No. III FURTHER APPLICANT(S) AND/OR (FURTHER) INVENTOR(S)*If none of the following sub-boxes is used, this sheet should not be included in the request.*

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

ENTIAN Karl-Dieter
Oberurseler Str 43
D-61440 OBERURSEL

This person is:

- ☐ applicant only
- ☒ applicant and inventor
- ☐ inventor only (If this check-box is marked, do not fill in below)

State (that is, country) of nationality:
DE

State (that is, country) of residence:
DE

This person is applicant for the purposes of: ☐ all designated States ☐ all designated States except the United States of America ☒ the United States of America only ☐ the States indicated in the Supplemental Box

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

KOETTER Peter
Industriestr 3A
D-61440 OBERURSEL

This person is:

- ☐ applicant only
- ☒ applicant and inventor
- ☐ inventor only (If this check-box is marked, do not fill in below)

State (that is, country) of nationality:
DE

State (that is, country) of residence:
DE

This person is applicant for the purposes of: ☐ all designated States ☐ all designated States except the United States of America ☒ the United States of America only ☐ the States indicated in the Supplemental Box

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

This person is:

- ☐ applicant only
- ☐ applicant and inventor
- ☐ inventor only (If this check-box is marked, do not fill in below)

State (that is, country) of nationality:

State (that is, country) of residence:

This person is applicant for the purposes of: ☐ all designated States ☐ all designated States except the United States of America ☐ the United States of America only ☐ the States indicated in the Supplemental Box

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

This person is:

- ☐ applicant only
- ☐ applicant and inventor
- ☐ inventor only (If this check-box is marked, do not fill in below)

State (that is, country) of nationality:

State (that is, country) of residence:

This person is applicant for the purposes of: ☐ all designated States ☐ all designated States except the United States of America ☐ the United States of America only ☐ the States indicated in the Supplemental Box

☐ Further applicants and/or (further) inventors are indicated on another continuation sheet.

Box No.V DESIGNATION OF STATES

The following designations are hereby made under Rule 4.9(a) (mark the applicable check-boxes; at least one must be marked):

Regional Patent

- ☒ **AP ARIPO Patent:** GH Ghana, GM Gambia, KE Kenya, LS Lesotho, MW Malawi, SD Sudan, SZ Swaziland, UG Uganda, ZW Zimbabwe, and any other State which is a Contracting State of the Harare Protocol and of the PCT
- ☒ **EA Eurasian Patent:** AM Armenia, AZ Azerbaijan, BY Belarus, KG Kyrgyzstan, KZ Kazakhstan, MD Republic of Moldova, RU Russian Federation, TJ Tajikistan, TM Turkmenistan, and any other State which is a Contracting State of the Eurasian Patent Convention and of the PCT
- ☒ **EP European Patent:** AT Austria, BE Belgium, CH and LI Switzerland and Liechtenstein, CY Cyprus, DE Germany, DK Denmark, ES Spain, FI Finland, FR France, GB United Kingdom, GR Greece, IE Ireland, IT Italy, LU Luxembourg, MC Monaco, NL Netherlands, PT Portugal, SE Sweden, and any other State which is a Contracting State of the European Patent Convention and of the PCT
- ☒ **OA OAPI Patent:** BF Burkina Faso, BJ Benin, CF Central African Republic, CG Congo, CI Côte d'Ivoire, CM Cameroon, GA Gabon, GN Guinea, GW Guinea-Bissau, ML Mali, MR Mauritania, NE Niger, SN Senegal, TD Chad, TG Togo, and any other State which is a member State of OAPI and a Contracting State of the PCT (if other kind of protection or treatment desired, specify on dotted line)

National Patent (if other kind of protection or treatment desired, specify on dotted line)

- | | |
|--|--|
| <input checked="" type="checkbox"/> AL Albania | <input checked="" type="checkbox"/> LS Lesotho |
| <input checked="" type="checkbox"/> AM Armenia | <input checked="" type="checkbox"/> LT Lithuania |
| <input checked="" type="checkbox"/> AT Austria | <input checked="" type="checkbox"/> LU Luxembourg |
| <input checked="" type="checkbox"/> AU Australia | <input checked="" type="checkbox"/> LV Latvia |
| <input checked="" type="checkbox"/> AZ Azerbaijan | <input checked="" type="checkbox"/> MD Republic of Moldova |
| <input checked="" type="checkbox"/> BA Bosnia and Herzegovina | <input checked="" type="checkbox"/> MG Madagascar |
| <input checked="" type="checkbox"/> BB Barbados | <input checked="" type="checkbox"/> MK The former Yugoslav Republic of Macedonia |
| <input checked="" type="checkbox"/> BG Bulgaria | <input checked="" type="checkbox"/> MN Mongolia |
| <input checked="" type="checkbox"/> BR Brazil | <input checked="" type="checkbox"/> MW Malawi |
| <input checked="" type="checkbox"/> BY Belarus | <input checked="" type="checkbox"/> MX Mexico |
| <input checked="" type="checkbox"/> CA Canada | <input checked="" type="checkbox"/> NO Norway |
| <input checked="" type="checkbox"/> CH and LI Switzerland and Liechtenstein | <input checked="" type="checkbox"/> NZ New Zealand |
| <input checked="" type="checkbox"/> CN China | <input checked="" type="checkbox"/> PL Poland |
| <input checked="" type="checkbox"/> CU Cuba | <input checked="" type="checkbox"/> PT Portugal |
| <input checked="" type="checkbox"/> CZ Czech Republic | <input checked="" type="checkbox"/> RO Romania |
| <input checked="" type="checkbox"/> DE Germany | <input checked="" type="checkbox"/> RU Russian Federation |
| <input checked="" type="checkbox"/> DK Denmark | <input checked="" type="checkbox"/> SD Sudan |
| <input checked="" type="checkbox"/> EE Estonia | <input checked="" type="checkbox"/> SE Sweden |
| <input checked="" type="checkbox"/> ES Spain | <input checked="" type="checkbox"/> SG Singapore |
| <input checked="" type="checkbox"/> FI Finland | <input checked="" type="checkbox"/> SI Slovenia |
| <input checked="" type="checkbox"/> GB United Kingdom | <input checked="" type="checkbox"/> SK Slovakia |
| <input checked="" type="checkbox"/> GD Grenada | <input checked="" type="checkbox"/> SL Sierra Leone |
| <input checked="" type="checkbox"/> GE Georgia | <input checked="" type="checkbox"/> TJ Tajikistan |
| <input checked="" type="checkbox"/> GH Ghana | <input checked="" type="checkbox"/> TM Turkmenistan |
| <input checked="" type="checkbox"/> GM Gambia | <input checked="" type="checkbox"/> TR Turkey |
| <input checked="" type="checkbox"/> HR Croatia | <input checked="" type="checkbox"/> TT Trinidad and Tobago |
| <input checked="" type="checkbox"/> HU Hungary | <input checked="" type="checkbox"/> UA Ukraine |
| <input checked="" type="checkbox"/> ID Indonesia | <input checked="" type="checkbox"/> UG Uganda |
| <input checked="" type="checkbox"/> IL Israel | <input checked="" type="checkbox"/> US United States of America |
| <input checked="" type="checkbox"/> IN India | |
| <input checked="" type="checkbox"/> IS Iceland | |
| <input checked="" type="checkbox"/> JP Japan | <input checked="" type="checkbox"/> UZ Uzbekistan |
| <input checked="" type="checkbox"/> KE Kenya | <input checked="" type="checkbox"/> VN Viet Nam |
| <input checked="" type="checkbox"/> KG Kyrgyzstan | <input checked="" type="checkbox"/> YU Yugoslavia |
| <input checked="" type="checkbox"/> KP Democratic People's Republic of Korea | <input checked="" type="checkbox"/> ZW Zimbabwe |
| <input checked="" type="checkbox"/> KR Republic of Korea | |
| <input checked="" type="checkbox"/> KZ Kazakhstan | |
| <input checked="" type="checkbox"/> LC Saint Lucia | <input checked="" type="checkbox"/> ZA |
| <input checked="" type="checkbox"/> LK Sri Lanka | <input checked="" type="checkbox"/> AE |
| <input checked="" type="checkbox"/> LR Liberia | <input type="checkbox"/> |

Check-boxes reserved for designating States (for the purposes of a national patent) which have become party to the PCT after issuance of this sheet:

Precautionary Designation Statement: In addition to the designations made above, the applicant also makes under Rule 4.9(b) all other designations which would be permitted under the PCT except any designation(s) indicated in the Supplemental Box as being excluded from the scope of this statement. The applicant declares that those additional designations are subject to confirmation and that any designation which is not confirmed before the expiration of 15 months from the priority date is to be regarded as withdrawn by the applicant at the expiration of that time limit. (Confirmation of a designation consists of the filing of a notice specifying that designation and the payment of the designation and confirmation fees. Confirmation must reach the receiving Office within the 15-month time limit.)

Supplemental Box

If the Supplemental Box is not used, this sheet should not be included in the request.

1. If, in any of the Boxes, the space is insufficient to furnish all the information: in such case, write "Continuation of Box No. . . ." [indicate the number of the Box] and furnish the information in the same manner as required according to the captions of the Box in which the space was insufficient, in particular:

- (i) if more than two persons are involved as applicants and/or inventors and no "continuation sheet" is available, in such case, write "Continuation of Box No. III" and indicate for each additional person the same type of information as required in Box No. III. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below;
- (ii) if, in Box No. II or in any of the sub-boxes of Box No. III, the indication "the States indicated in the Supplemental Box" is checked, in such case, write "Continuation of Box No. II" or "Continuation of Box No. III" or "Continuation of Boxes No. II and No. III" (as the case may be), indicate the name of the applicant(s) involved and, next to (each) such name, the State(s) (and/or, where applicable, ARIPO, Eurasian, European or OAPI patent) for the purposes of which the named person is applicant;
- (iii) if, in Box No. II or in any of the sub-boxes of Box No. III, the inventor or the inventor/applicant is not inventor for the purposes of all designated States or for the purposes of the United States of America, in such case, write "Continuation of Box No. II" or "Continuation of Box No. III" or "Continuation of Boxes No. II and No. III" (as the case may be), indicate the name of the inventor(s) and, next to (each) such name, the State(s) (and/or, where applicable, ARIPO, Eurasian, European or OAPI patent) for the purposes of which the named person is inventor;
- (iv) if, in addition to the agent(s) indicated in Box No. IV, there are further agents, in such case, write "Continuation of Box No. IV" and indicate for each further agent the same type of information as required in Box No. IV;
- (v) if, in Box No. V, the name of any State (or OAPI) is accompanied by the indication "patent of addition," or "certificate of addition," or if, in Box No. V, the name of the United States of America is accompanied by an indication "continuation" or "continuation-in-part": in such case, write "Continuation of Box No. V" and the name of each State involved (or OAPI), and after the name of each such State (or OAPI), the number of the parent title or parent application and the date of grant of the parent title or filing of the parent application;
- (vi) if, in Box No. VI, there are more than three earlier applications whose priority is claimed: in such case, write "Continuation of Box No. VI" and indicate for each additional earlier application the same type of information as required in Box No. VI;
- (vii) if, in Box No. VI, the earlier application is an ARIPO application: in such case, write "Continuation of Box No. VI", specify the number of the item corresponding to that earlier application and indicate at least one country party to the Paris Convention for the Protection of Industrial Property for which that earlier application was filed.

2. If, with regard to the precautionary designation statement contained in Box No. V, the applicant wishes to exclude any State(s) from the scope of that statement: in such case, write "Designation(s) excluded from precautionary designation statement" and indicate the name or two-letter code of each State so excluded.

3. If the applicant claims, in respect of any designated Office, the benefits of provisions of the national law concerning non-prejudicial disclosures or exceptions to lack of novelty: in such case, write "Statement concerning non-prejudicial disclosures or exceptions to lack of novelty" and furnish that statement below.

Supplemental BOX IV

DESROUSSEAUX Grégoire
CORTEY Pierre
CABINET HIRSCH -DESROUSSEAUX - POCHART
34 rue de Bassano
75008 PARIS
FRANCE

Box No. VI PRIORITY CLAIM		<input type="checkbox"/> Further priority claims are indicated in the Supplemental Box.		
Filing date of earlier application (day/month/year)	Number of earlier application	Where earlier application is:		
		national application: country	regional application:* regional Office	international application: receiving Office
item (1) 24/04/98	98401007.4	EP		
item (2) 11/09/98	98402254.1	EP		
item (3)				

☒ The receiving Office is requested to prepare and transmit to the International Bureau a certified copy of the earlier application(s) (only if the earlier application was filed with the Office which for the purposes of the present international application is the receiving Office) identified above as item(s) 1 and 2

* Where the earlier application is an ARIPO application, it is mandatory to indicate in the Supplemental Box at least one country party to the Paris Convention for the Protection of Industrial Property for which that earlier application was filed (Rule 4.10(b)(iii)). See Supplemental Box

Box No. VII INTERNATIONAL SEARCHING AUTHORITY

Choice of International Searching Authority (ISA) (if two or more International Searching Authorities are competent to carry out the international search, indicate the Authority chosen; the two-letter code may be used):	Request to use results of earlier search; reference to that search (if an earlier search has been carried out by or requested from the International Searching Authority)		
ISA / EP	Date (day/month/year)	Number	Country (or regional Office)
	24/04/98	98401007.4	EP
	11/09/98	98402254.1	EP

Box No. VIII CHECK LIST; LANGUAGE OF FILING


This international application contains the following number of sheets:	This international application is accompanied by the item(s) marked below:
request 5	1. <input checked="" type="checkbox"/> fee calculation sheet
description (excluding sequence listing part) 41	2. <input type="checkbox"/> separate signed power of attorney
claims 3	3. <input type="checkbox"/> copy of general power of attorney; reference number, if any:
abstract 1	4. <input type="checkbox"/> statement explaining lack of signature
drawings	5. <input type="checkbox"/> priority document(s) identified in Box No. VI as item(s)
sequence listing part of description 40	6. <input type="checkbox"/> translation of international application into (language):
Total number of sheets 90	7. <input type="checkbox"/> separate indications concerning deposited microorganism or other biological material
	8. <input checked="" type="checkbox"/> nucleotide and/or amino acid sequence listing in computer readable form
	9. <input checked="" type="checkbox"/> other (specify): Search Report 98401007.4
Figure of the drawings which should accompany the abstract:	Language of filing of the international application: English

Box No. IX SIGNATURE OF APPLICANT OR AGENT

Next to each signature, indicate the name of the person signing and the capacity in which the person signs (if such capacity is not obvious from reading the request)

Paris April 21, 1999

POCHART François



For receiving Office use only		2. Drawings: <input type="checkbox"/> received <input type="checkbox"/> not received:
1. Date of actual receipt of the purported international application:		
3. Corrected date of actual receipt due to later but timely received papers or drawings completing the purported international application:		
4. Date of timely receipt of the required corrections under PCT Article 11(2):		
5. International Searching Authority (if two or more are competent): ISA /	6. <input type="checkbox"/> Transmittal of search copy delayed until search fee is paid.	

For International Bureau use only

Date of receipt of the record copy by the International Bureau:



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12Q 1/68, 1/18	A2	(11) International Publication Number: WO 99/55907 (43) International Publication Date: 4 November 1999 (04.11.99)
<p>(21) International Application Number: PCT/EP99/02722</p> <p>(22) International Filing Date: 22 April 1999 (22.04.99)</p> <p>(30) Priority Data: 98401007.4 24 April 1998 (24.04.98) EP 98402254.1 11 September 1998 (11.09.98) EP</p> <p>(71) Applicant (<i>for all designated States except US</i>): HOECHST MARION ROUSSEL [FR/FR]; 1, terrasse Bellini, F-92800 Puteaux (FR).</p> <p>(72) Inventors; and (75) Inventors/Applicants (<i>for US only</i>): DIU-HERCEND, Anita [FR/FR]; 39, rue Gabrielle, F-94220 Charenton le Pont (FR). ENTIAN, Karl-Dieter [DE/DE]; Oberurseler Strasse 43, D-61440 Oberursel (DE). KOETTER, Peter [DE/DE]; Industriestrasse 3A, D-61440 Oberursel (DE).</p> <p>(74) Agents: POCHART, François et al.; Cabinet Hirsch-Desrousseaux-Pochart, 34, rue de Bassano, F-75008 Paris (FR).</p>		<p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>Without international search report and to be republished upon receipt of that report.</i></p>
<p>(54) Title: METHOD FOR SCREENING ANTIMYCOTIC SUBSTANCES USING ESSENTIAL GENES FROM S. CEREVISIAE</p> <p>(57) Abstract</p> <p>The present invention concerns a method for the screening of antimycotic substances wherein an essential gene from mycetes or a functionally similar mycete gene, or the corresponding encoded protein, is used as target and wherein the essential gene is selected from the group consisting in YML114c, YLR186w, YLR215c, YLR222c, YLR243w, YLR272c, YLR275w, YLR276c, YLR317w, YLR359w, YLR373c, YLR424w, YLR437c, YLR440c, YML023c, YML049c, YML077w, YML093w, YML127w, YMR032w, YMR093w, YMR131c, YMR185w, YMR212c, YMR213w, YMR218c, YMR281w, YMR288w, YMR290c, YMR211w, YMR049c, YMR134w, YDR196c, YDR299w, YDR365c, YDR396w, YDR407c, YDR416w, YDR449c, YDR472w, YDR499w, YDR141c, YDR324c, YDR325w, YDR398w, YDR246w, YDR236c, YDR361c, YDR367w, YDR339c, YDR413c, YDR429c, YDR468c, YDR489w, YDR527w, YDR288w, YDR201w, YDR434w, YDR181c, YDR531w, YPL126w, YPL093w, YPL063w, YPL024w, YPL020c, YPL012w, YPL007c, YPL233w, YPL146c, YIL091c, YIL083c, YIL019w, YIL109c, YIL104c, YFL024c, YFR003c, YFR027w, YFR042w, YIR010w, YIR015w, YPR048w, YPR072w, YPR082c, YPR085c, YPR105c, YPR112c, YPR137w, YPR143w, YPR144c and YPR169w.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

METHOD FOR SCREENING ANTIMYCOTIC SUBSTANCES USING ESSENTIAL GENES FROM *S. CEREVISIAE*

The present invention relates to a method for screening for antimycotic substances in which essential genes from mycetes, particularly from *Saccharomyces cerevisiae* (*S.cerevisiae*) as well as functionally similar genes from other mycetes, or the corresponding encoded proteins, are used as targets.

The spectrum of known fungal infections stretches from fungal attack of skin or nails to potentially hazardous mycotic infections of the inner organs; Such infections and resulting diseases are known as mycosis.

Antimycotic substances (fungistatic or fungicidal) are used for treatment of mycosis. However, up to now, relatively few substances with pharmacological effects are known, such as Amphotericin B, Nystatin, Pimaricin, Griseofulvin, Clotrimazole, 5-fluoro-cytosine and Batraphene. The drug treatment of fungal infections is extremely difficult, in particular because both the host cells and the mycetes, are eukaryotic cells. Administration of drugs based on known antimycotic substances results therefore often in undesired side-effects, for example Amphotericin B has a nephrotoxic effect. Therefore, there is a strong need for pharmacologically efficient substances usable for the preparation of drugs, which are suitable for prophylactic treatments of immunodepressive states or for the treatment of an existing fungal infection. Furthermore, the substances should exhibit a specific spectrum of action in order to selectively inhibit the growth and proliferation of mycetes without affecting the treated host organism.

The aim of the present invention is to provide a method for the identification of antimycotic substances. An essential feature of this method is that essential genes from mycetes are used as targets for the screening.

The present invention thus concerns a method for screening antimycotic substances wherein an essential gene

CONFIRMATION COPY

from mycetes or a functionally similar gene in another mycete, or the corresponding encoded protein, is used as target and wherein the essential gene is selected from the group consisting in YML114c, YLR186w, YLR215c, YLR222c, YLR243w, YLR272c, YLR275w, YLR276c, YLR317w, YLR359w, YLR373c, YLR424w, YLR437c, YLR440c, YML023c, YML049c, YML077w, YML093w, YML127w, YMR032w, YMR093w, YMR131c, YMR185w, YMR212c, YMR213w, YMR219c, YMR281w, YMR288w, YMR290c, YMR211w, YMR049c, YMR134w, YDR196c, YDR299w, YDR365c, YDR396w, YDR407c, YDR416w, YDR449c, YDR472w, YDR499w, YDR141c, YDR324c, YDR325w, YDR398w, YDR346w, YDR236c, YDR361c, YDR367w, YDR339c, YDR413c, YDR429c, YDR468c, YDR489w, YDR527w, YDR388w, YDR201w, YDR434w, YDR181c, YDR531w, YPL126w, YPL093w, YPL063w, YPL024w, YPL020c, YPL012w, YPL007c, YPL133w, YPL146c, YIL091c, YIL083c, YIL019w, YIL109c, YIL104c, YFL024c, YFR003c, YFR027w, YFR042w, YIR010w, YIR015w, YPR048w, YPR072w, YPR082c, YPR085c, YPR105c, YPR112c, YPR137w, YPR143w, YPR144c and YPR169w.

According to one embodiment of the method of the invention mycete cells which express the essential gene, or a functionally similar mycete gene, to a different level are incubated with the substance to be tested and the growth inhibiting effect of the substance is determined.

According to another embodiment, said target gene or the corresponding target gene encoded protein is contacted in vitro with the substance to be tested and the effect of the substance on the target is determined.

According to another embodiment, the screened substances inhibit partially or totally the functional expression of the essential genes or the functional activity of the encoded proteins.

According to another embodiment, the mycete species are selected from the group comprising Basidiomycetes, Ascomycetes and Hyphomycetes.

According to another embodiment of the method of the invention said functional similar genes are essential genes from *Candida* Spp., preferably *Candida albicans*, or

from *Aspergillus* Spp., preferably from *Aspergillus fumigatus*.

According to a further embodiment of the above method said mycete cells are haploid *S.cerevisiae* cells.

According to a particular embodiment of the method of the invention the essential genes of *S.cerevisiae* are identified by integrating by homologous recombination a selection marker at the locus of the gene to be studied.

The present invention also concerns a method as described above wherein the functionally similar genes are identified by:

a) providing a *S.cerevisiae* mutant strain in which the gene of *S.cerevisiae* to be investigated is either integrative or extrachromosomal under the control of a regulated promoter,

b) culturing said mutant strain under growth conditions in which the regulated promoter is active,

c) transforming the mutant strain with a cDNA or genomic DNA that has been prepared from the heterologous mycete-species and that has been integrated into an appropriate vector,

d) altering the culture condition, so that the regulated promoter is switched off and only *S.cerevisiae* cells which contain a functionally similar gene can survive,

e) isolating and analyzing the cDNA or genomic DNA.

The invention thus discloses that in a first step, essential genes from *S.cerevisiae* are identified. The invention also discloses that, essential genes from other mycetes are identified starting from the identified essential genes in *S.cerevisiae*. In order to identify essential genes of *S.cerevisiae*, individual genomic genes are eliminated through homologous recombination. If the DNA segment thus eliminated concerns an essential gene, then the deletion is lethal for the *S.cerevisiae* cells in haploid form.

A method, wherein the studied *S.cerevisiae* gene is replaced by a marker gene can be used to generate the

corresponding genomic deletion of *S.cerevisiae* and to determine the *S.cerevisiae* cells containing the deletion.

As a selection marker a dominant selection marker (e.g. kanamycin resistance gene) or an auxotrophic marker can for example be used. As an auxotrophic marker, it is possible to use genes coding for key enzymes of amino acid or nucleic base synthesis. For example, one can use as a selection marker the following genes from *S.cerevisiae* : gene encoding for the metabolic pathway of leucine (e.g. LEU2-gene), histidine (e.g. HIS3-gene) or tryptophan (e.g. TRP1 gene; or for the nucleic base metabolism of uracil (e.g. URA3-gene).

Auxotrophic *S.cerevisiae* strains can be used. These auxotrophic strains can only grow on nutritive media containing the corresponding amino acids or nucleotide bases. All laboratory *S.cerevisiae* strains, containing auxotrophic markers can for instance be used. When diploid *S.cerevisiae* strains are used, then the corresponding marker gene must be homozygously mutated. Strain CEN.PK2 or isogenic derivatives thereof can be used.

Strains containing no suitable auxotrophic marker can also be used such as prototrophic *S.cerevisiae* strains. Then a dominant selection marker e.g. resistance gene, such as kanamycin resistance gene can be used. A loxP-KanMX-loxP cassette can advantageously be used for this purpose.

For the homologous recombination replacing the whole DNA sequence or part thereof of a *S.cerevisiae* gene, DNA fragments are used wherein the marker gene is flanked at the 5'- and 3'-ends by sequences which are homologous to the 5'- and 3'-ends of the studied *S.cerevisiae* gene.

Different processes can be used for the preparation of the corresponding DNA fragments which are also appropriate for the deletion of any specific *S.cerevisiae* gene. A linear DNA-fragment is used for the transformation of the suitable *S.cerevisiae* strain. This fragment is integrated into the *S.cerevisiae* genome by homologous recombination. These processes include:

1. "Conventional method" for the preparation of deletion cassettes (Rothstein, R.J. (1983) Methods in Enzymology, Vol. 101, 202-211).

2. "Conventional Method" using the PCR technique ("modified conventional method").

3. SFH (short flanking homology)- PCR method (Wach, A. et al. (1994) Yeast 10: 1793-1808; Gültner, U. et al. (1996) Nucleic Acids Research 24:2519-2524).

1. In the "conventional method" for the preparation of deletion cassettes in the *S.cerevisiae* genome, the gene to be studied is either already present in an appropriate vector or is integrated in such a vector. With this method, any pBR- pUC- and pBluescript"-derivates can be used for example. A major part of the target gene sequence is eliminated from the vector, for instance using appropriate restriction sites, conserving however the 3'- and 5'-regions of the studied gene inside the vector. The selected marker gene is integrated between the remaining regions.

2. In the modified form of this "conventional method", PCR is used. This method allows amplification of the 3'- and 5'-terminal regions of the coding sequence of the studied *S.cerevisiae* gene. This method amplifies selectively both terminal regions of the studied gene, therefore, two PCR-reactions must be carried out for each studied gene, amplifying once the 5'-end, and once the 3'-end of the gene. The length of the amplified terminal DNA-fragment depends on the existing restriction sites. The amplified terminal ends of the studied gene have generally a length of 50 to 5000 base pairs (bp), preferably a length between 500 and 1000 bp.

As template for the PCR-reactions, genomic DNA of *S.cerevisiae* or wild-type genes can be used. The primer-pairs (a sense and an antisense primer, respectively) are constructed so that they correspond to the 3'-end and the 5'-end sequence of the studied *S.cerevisiae* gene. Especially, the primer is selected such as to allow its integration by way of appropriate restriction sites.

As vectors, pBR- pUC- and pBluescript"-derivates can be used. In particular vectors already containing a

gene encoding the selection marker, are appropriate. In particular, vectors can be used, which contain genes of the selection marker HIS3, LEU2, TRP1 or URA3.

The DNA segments of the studied *S.cerevisiae* gene, obtained by PCR, are integrated in the vector at both sides of the selection marker, so that subsequently, as in the "conventional method", the selection marker is flanked on both ends by DNA sequences which are homologous to the studied gene.

3. Homologous recombination in *S.cerevisiae* takes place in a very efficient and precise manner and the length of the DNA sequence homologous to the studied *S.cerevisiae* gene flanking the selection marker gene can in fact be considerably shorter than with the "modified conventional method". The flanking ends homologous to the studied *S.cerevisiae* gene need to present a length of only about 20-60 bp, preferably 30-45 bp. The SFH-PCR method is particularly advantageous as the laborious cloning step can be obviated.

A PCR reaction is carried out on a DNA-template containing the gene for the selection marker to be used, wherein the primers are constructed so that the DNA sequence of the sense primer is homologous to the 5'-end of the selection marker sequence and so that the primer presents in addition at its 5'-end a region of preferably 40 nucleotides, which corresponds to the 5'-terminal sequence of the studied *S.cerevisiae* gene. The antisense primer is constructed in an analogous manner, i.e. it is complementary to the 3'-end of the gene sequence of the selection marker, wherein this primer contains at its 5'-end a region of also preferably 40 nucleotides, which corresponds to the complementary strand of the 3'-terminal coding sequence of the studied gene.

For the amplification of *S.cerevisiae* genes to be studied by the SFH-PCR method, vectors containing the gene for the auxotrophic marker or selection marker can be used. Especially, plasmid pUG6 is used as the template. This plasmid contains a loxP-KanMX-loxP cassette (Gültner, U. et al. (1996) Nucleic Acids Research 24: 2519-2524). In other

terms, the Kanamycin resistance gene is flanked at both ends by a loxP sequence (loxP-KanMX-loxP cassette). This cassette is advantageous in that the Kanamycin resistance gene can be eventually eliminated from the *S.cerevisiae* genome after integration of the loxP-KanMX-loxP cassette into the *S.cerevisiae* gene to be studied. Cre-recombinase of bacteriophage P1 can be used for this purpose. Cre-recombinase recognizes the loxP sequences and induces elimination of the DNA located between the two loxP sequences by a homologous recombination process. As a result only one loxP sequence remains and the so-called marker regeneration occurs, i.e. the *S.cerevisiae* strain may be transformed again using the loxP-KanMX-loxP cassette. This is particularly advantageous, when at least two functionally similar genes are to be deleted in order to obtain a lethal phenotype.

With the PCR-method, the PCR reaction primers are at the 3'-end a preferably 20 nucleotide long sequence, which is homologous to the sequence situated left and/or right of the loxP-KanMX-loxP cassette, and at the 5'-end a preferably 40 nucleotide long sequence, which is homologous to the terminal ends of the gene to be studied.

Using the three methods, one obtains linear deletion cassettes containing the gene encoding the selection marker, which is flanked on both sides by homologous sequences of the gene to be studied. The deletion cassettes are used for the transformation of diploid *S.cerevisiae* strains. The diploid strain *S.cerevisiae* CEN.PK2 (Scientific Research & Development GmbH, Oberursel) can be used for example for this purpose. [CEN.PK2 Mata/MAT α ura3-52/ura3-52 leu2-3, 112/leu2-3, 112his3 Δ 1/his3 Δ 1 trp1-289/trp1-289 MAL2-8^C/MAL2-8^C SUC2/SUC2]

The strain CEN.PK2 is prepared and cultivated using known methods (Gietz, R.D. et al. (1992) Nucleic Acids Research 8: 1425; Güldener, U. et al. (1996) Nucleic Acids Research 24:2519-2524).

The cells of the *S.cerevisiae* strain used are transformed according to known processes with an appropriate DNA quantity of the linear deletion cassette (e.g. Sambrook et al. 1989). Thereafter, the medium in which the cells are cultivated is replaced by a new medium, a so-called selective medium, which does not contain the corresponding amino acid (e. g. histidine, leucine or tryptophan) or nucleic base (e. g. uracil) or, when using a deletion cassette containing the kanamycin resistance gene, by a medium containing geneticin (G418[®]) (e.g. a complete medium (YEPD) containing geneticin). Alternatively, the transformed cells may be plated on agar plates prepared using the corresponding media. Thereby, one selects the transformed cells, in which a homologous recombination occurred, since only those cells can grow under these modified conditions.

However, in most cases, only one of the two copies of the gene in the double chromosome set of a diploid *S.cerevisiae* strain is replaced by the DNA of the deletion cassette during the transformation, resulting in a heterozygote-diploid *S.cerevisiae* mutant strain, wherein one copy of the gene studied is replaced by a selection marker, while the other copy of the gene is maintained in the genome. This presents the advantage that in case of a deletion of an essential gene, due to the existence of the second copy of the essential gene, the mutant *S.cerevisiae* strain is still viable.

The proper integration of the deletion cassette DNA at the predetermined chromosomal gene locus (gene locus of the gene to be studied) may be checked by Southern-Blot Analysis (Southern, E.M. (1975) J. Mol. Biol. 98:503-517) or by diagnostic PCR analysis using specific primers (Guldener, U. et al. (1996) Nucleic Acids Research 24:2519-2524).

The genetic separation of individual diploid cells may be monitored by tetrad analysis. To this end, reduction division (meiosis) is induced in the diploid cells, especially heterozygote mutant strains, using known methods such as nitrogen impoverishment on potassium acetate plates

(Sherman, F. et al. (1986) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N. Y.; Guthrie, C. and Fink, G.R. (1991) Methods in Enzymology, Vol 194. Academic Press, San Diego, 3-21; Ausubel, F. M. et al. (1987) Current Protocol in Molecular Biology John Wiley and Sons, Inc., Chapter 13). Meiosis results only in asci with four ascospores (segregated), which can be individualized after partial enzymatic digestion of the ascospore wall with zymolyase (Ausubel et al. (1987)) by way of micromanipulators (e.g. SINGER). For example when a tetrad analysis is carried out on a heterozygote-diploid mutant strain in which an essential gene present in the double chromosome set is replaced on one chromosome by homologous recombination, then only two segregated ascospores are viable, namely those which carry the essential gene. The two remaining segregated ascospores are not viable because they lack the essential gene.

In order to check if the genes studied by this method are really essential or if the homologous recombination leads to an alteration of an essential gene adjacent to the gene locus of the gene studied, the heterozygote diploid *S.cerevisiae* mutant strain is transformed with a centromere plasmid containing said studied gene.

A tetrad analysis is carried out on the transformants. When four instead of two viable segregates are obtained, then the studied gene contained in the centromere plasmid can complement the defect of the two non-viable haploid *S.cerevisiae* cells/mutant strains, which demonstrates that the studied *S.cerevisiae* gene is essential.

Preferably, plasmids present in low copy number, e.g. one or two copies per cell are used as centromere plasmids. For example plasmids pRS313, pRS314, pRS315 and pRS316 (Sijkorski, R. S. and Hieter, P. (1989) Genetics 122: 19-27) or similar plasmids can be used for this purpose. Preferably, the studied genes are integrated in said plasmids including their 3'- and 5'-end non-coding regions.

Individual *S.cerevisiae* genes may be studied using the above-described method, their sequences being totally or partially known. The complete genomic sequence of *S.cerevisiae* was made accessible to the public via the WWW (World Wide Web) on April 24, 1996.

Different possibilities exist to have access to the *S.cerevisiae* genomic DNA sequence via the WWW.

MIPS (Munich information Centre of Protein Sequence) Address <http://speedy.mips.biochem.mpg.de/mips/yeast/>

SGD (Saccharomyces Genome Database, Stanford) Address <http://genome-www.stanford.edu/Saccharomyces>
YPD(Yeast Protein Database, Cold Spring Harbor) Address <http://www.proteome.com/YPDhome.html>

The complete *S.cerevisiae* DNA sequence is also accessible via FTP (file transfer protocol) in Europe (e.g. at the address: <ftp:mips.embnet.org>) in the U.S.A. (address: <genome-ftp.stanford.edu>) or in Japan (address: <ftp.nig.ac.jp>).

The complete *S.cerevisiae* DNA sequence was published in Nature, special issue No 387, 1997.

90 essential genomic *S.cerevisiae* genes have been identified by this way. These essential genes are listed in table 1. Table 1 contains the systematic gene name of the essential genes (corresponding to the denomination under which the corresponding DNA sequences are accessible in databanks), the deleted nucleotides and the corresponding amino acids of the essential genes (position 1 is taken as reference, this latter corresponding to the A of the probable initiation codon ATG of the ORF). The deleted nucleotides correspond to nucleotides deleted in the gene and the deleted amino acids correspond to the amino acids missing in the encoded protein. Furthermore aa corresponds to the total number of amino acids present in the encoded protein. The numbers of deleted nucleotides do not necessarily correspond to 3 times the numbers of deleted amino acids; this is explained by the fact that a gene is bigger than the encoded reading frame for amino acids. YMR134w for example encodes a protein of 237aa, the

deletion starts at nucleotide 5 (counting starts from ATG) and continues until nucleotide 740, this also includes part of the terminator region which does not encode aa, so the deletion of the aa starts from aa 2 until the end of the protein which is aa 237. Furthermore, the information available concerning the functions of respective genes or of the encoded proteins and/or homologies/similarities to other genes or proteins are indicated. The primers used for the PCR reaction to prepare the DNA fragments appropriate for the deletion of the genes are listed in table 2, where S1 and S2 are the forward and reverse primers, respectively, and the bold letters corresponding to the nucleotides of the respective gene.

The data of table 1 emphasize that despite the fact that the *S.cerevisiae* gene DNA sequences are known, very little is known today about the function, the characteristic properties of these genes, the essential function of these genes, or the proteins encoded by the same.

According to one embodiment of the method, essential genes of *S.cerevisiae* are used to identify corresponding functionally similar genes in other mycetes.

By functionally similar genes in other mycete species, is meant genes which have a function similar or identical to that of the identified essential genes of *S.cerevisiae*. Functionally similar genes in other mycetes may, but need not be homologous in sequence to the corresponding essential *S.cerevisiae* genes. Functionally similar genes in other mycetes may exhibit only moderate sequence homology at the nucleotide level to the corresponding essential *S.cerevisiae* genes. By moderate sequence homology it is meant in the present invention genes having a sequence identity, at the nucleotide level, of at least 50%, more preferably of at least 60% and most preferably of at least 70%.

In addition, functionally similar genes in other mycetes may, but need not encode proteins homologous in sequence to the proteins encoded by the essential *S.cerevisiae* genes. Functionally similar proteins in other

mycetes may exhibit moderate protein sequence homology to the proteins encoded by the essential *S.cerevisiae* genes.

By moderate protein sequence homology is meant in the present invention proteins having a sequence identity, at the amino-acid level, of at least 40%, preferably of at least 50%, more preferably of at least 60% and most preferably of at least 70%.

Genes homologous in sequence may be isolated according to known methods, for example via homologous screening (Sambrook, J. et al. (1989) Molecular Cloning Cold Spring Harbor Laboratory Press, N.Y.) or via the PCR technique using specific primers from genomic libraries and/or cDNA libraries of the corresponding mycetes.

According to one embodiment, genes homologous in sequences are isolated from cDNA libraries. In order to find out functionally similar genes in other mycetes, mRNA is isolated from mycete species to be studied according to known methods (Sambrook et al. 1989) and cDNA is synthesized according to known methods (Sambrook et al. 1989; or cDNA synthesis kits, e.g. from STRATAGENE).

The prepared cDNA is directionally integrated in a suitable expression vector.

For example, synthesis of the first cDNA strand may be carried out in the presence of primers having appropriate restriction sites in order to allow a subsequent cloning in the proper orientation with respect to the expression vector promoter. As restriction sites, any known restriction site may be used. As a primer, for instance the following primer, 50 nucleotides long may be used:

5'-GAGAGAGAGAGAGAGAGAGAGAACTAGTXXXXXXTTTTTTTTTTTTTTTTTTT-3'

The sequence (X)₆ represents an appropriate restriction site, for example for XhoI.

After two-strand synthesis, the cohesive ends of the double stranded cDNA are filled (blunt end) and the cDNA ends are then ligated using a suitable DNA adaptor sequence. The DNA adaptor sequence should contain a restriction site which should be different from the restriction site used in the primer for the synthesis of

the first cDNA strand. The DNA adaptor may comprise for example complementary 9- or 13-mer oligonucleotides, whose ends represent the cohesive end of a restriction site. These ends may be for example a EcoRI-site:

```
5'      XXXXXGGGACGAG 3'
3'      XCCGTGCTC 5'
```

The single-stranded X in the adaptor sequence represent the cohesive end of a restriction site.

The cDNA provided with corresponding adaptor sequences is then cleaved using restriction endonuclease, whose recognition site was used in the primer for the synthesis of the first cDNA strand, for example XhoI. The cDNA thus obtained would have according to this example 3'-XhoI and 5'-EcoRI protruding ends and could be therefore directionally integrated into an expression vector cleaved with XhoI and EcoRI.

As expression vectors, among others, E. coli/S.cerevisiae shuttle vectors, i.e. vectors usable in E. coli as well as in S.cerevisiae are suitable. Such vectors may then be amplified for instance in E. coli. As expression vectors, those which are present in a high copy number as well as those present in a low copy number in S.cerevisiae cells can be used. For this purpose, for example vectors selected in the group consisting of pRS423 - pRS426 (pRS423, pRS424, pRS425, pRS426) and/or pRS313-pRS316 (pRS313, pRS314, pRS315, pRS316) (Sikorki, R.S. and Hieter, P. (1989) Genetics 122: 19-27; Christianson T. W. et al. (1992) Gene 110: 119-122) are suitable.

Expression vectors should contain appropriate S.cerevisiae promoters and terminators. In case they do not have these elements, the corresponding promoters and terminators are inserted in such a way that a subsequent incorporation of the generated cDNA remains possible. Particularly suitable are the promoters of S.cerevisiae genes MET25, POK1, TPI1, TDH3, ADHI, URA3. One may use promoters of the wild-type gene in non modified form as well as promoters which were modified in such a way that certain activator sequences and/or repressor sequences were eliminated. As terminators, for example the terminators of

the *S.cerevisiae* genes MET25, PGK1, TFI1, TDH3, ADH1, URA3 are suitable.

According to another embodiment, genes homologous in sequence are isolated from genomic libraries. Genomic DNA libraries from mycetes can be prepared according to procedures known (for example as described in Current Protocols in Molecular Biology, John Wiley and Sons, Inc). For example, genomic DNA from mycetes can be prepared using known methods for yeast cell lysis and isolation of genomic DNA (for example commercially available kits from Bio101, Inc). The genomic DNA can be partially digested using a restriction enzyme such as Sau3AI and the fragments are size-selected by agarose gel electrophoresis. DNA fragments having for example a size of 5-10kb are then purified by classical methods (as for example, using Gene Clean kit from Bio101) and inserted in a *E.coli*/yeast shuttle vector such as YEP24 (described e.g. by Sanglard D., Kuchler K., Ischer F., Pagani J-L., Monod M. and Bille J., Antimicrobial Agents and Chemotherapy, (1995) Vol.39 No11, P2378-2386) cut by a restriction enzyme giving compatible ends (for example BamHI for Sau3AI-cut genomic DNA). The resulting expression library can be amplified in *E.coli*. However any known method, appropriate for the preparation of a genomic library, can be used in the present invention.

In order to find the genes in the studied mycete species, which are functionally similar to essential genes of *S.cerevisiae*, one *S.cerevisiae* essential gene is placed under control of a regulated promoter, either as an integrative (1) or extrachromosomal (2) gene.

1. For the integration of a regulated promoter in the *S.cerevisiae* genome, one replaces the native promoter of the selected essential gene by the regulated promoter, for example by homologous recombination via PCR (Gildener et al. (1996)). The homologous recombination via PCR can be carried out for example in the diploid *S.cerevisiae* strain CEN.PK2. The successful integration into one chromosome can be checked in haploid cells following tetrad analysis.

Using the tetrad analysis, one obtains four viable ascospores, wherein in two haploid segregates, the selected essential gene is placed under the control of the native promoter, while the essential gene in the two remaining segregates is placed under the control of the regulated promoter.

The last mentioned haploid segregates are used for the transformation with the cDNA or the genomic DNA present in the recombinant vector.

2. Using the extrachromosomal variant, the selected essential *S.cerevisiae* gene, is first inserted in a suitable expression vector, for example a *E.coli/S.cerevisiae* shuttle vector. For this purpose, the essential gene may be amplified via PCR from genomic *S.cerevisiae* DNA starting from the ATG initiation codon up to and including the termination codon. The primers used for this purpose may be constructed in such a way that they contain recognition sites for appropriate restriction enzymes, facilitating a subsequent insertion under control of a regulated promoter in an expression vector.

The recombinant expression vector with the plasmid copy of the essential *S.cerevisiae* gene under the control of a regulated promoter is subsequently used for the transcomplementation of the corresponding mutant allele. The corresponding mutant allele may be selected from the heterozygote-diploid mutant strains prepared by eliminating, partially or totally, by homologous recombination an essential mycete gene listed in table 1 (first column of table 1), as described above.

The expression vector with the selected essential *S.cerevisiae* gene is transformed in the corresponding heterozygote-diploid mutant strain carrying instead of the selected essential *S.cerevisiae* gene, a selection marker gene. The transformants are isolated by selection based on the auxotrophic marker contained in the expression vector used. The thus transformed heterozygote-diploid mutant strains are submitted to a tetrad analysis. One obtains four viable segregates. By retracing the corresponding markers of the mutant allele and the expression vector, the

transformed wild-type segregates may be distinguished from segregates which do not contain the genomic copy of the essential gene. Segregates, which do not contain the genomic copy of the selected essential gene, are designated as trans-complemented haploid mutant strains. They are subsequently used for transformation with cDNA or genomic DNA libraries from other mycete species present in appropriate vectors.

As regulated promoters, inducible or repressible promoters may be used. These promoters can consist of naturally and/or artificially disposed promoter sequences.

As regulated promoters, for example the promoters of GAL1 gene and the corresponding promoter derivatives, such as for example promoters, whose different UAS (upstream activation sequence) elements have been eliminated (GALS, GALL; Mumberg, J. et al. (1994) Nucleic Acids Research 22:5767-5768) may be used. As regulated promoters, promoters of gluconeogenic genes may also be used, such as e.g. FBPI, PCK1, ICL1 or parts therefrom, such as e.g. their activation sequence (UAS1 and/or UAS2) or repression sequence (URS, upstream repression sequence) (Niederacher et al. (1992), Curr. Genet. 22: 636-670; Proft et al. (1995) Mol. Gen. Genet. 246: 367-373; Schüller et al. (1992) EMBO J; 11: 107-114; Guarente et al. (1984) Cell 36: 503-511).

A *S.cerevisiae* mutant strain modified in this manner can be cultivated under growth conditions, in which the regulated promoter is active, so that the essential *S.cerevisiae* gene is expressed. The *S.cerevisiae* cells are then transformed with a representative quantity of the library containing the studied mycete species cDNA or genomic DNA. Transformants express additionally the protein whose coding sequence is present in the recombinant vector.

The method contemplates that the growth conditions may be modified in such a way as to inhibit the regulated promoter, under the control of which is the selected essential gene. Especially, growth conditions may be changed by replacing the growth medium. When for example the GAL1 promoter or a derivate thereof is used, one can

replace the galactose-containing medium (induced state) by a glucose-containing medium (repressed state).

These modified conditions are lethal for the *S.cerevisiae* cells in which the recombinant vector does not carry the functionally similar genomic DNA or cDNA of the studied mycete species. On the contrary, the *S.cerevisiae* cells in which the recombinant vector expresses a functionally similar coding sequence of the studied mycete species, are viable, since in these cells the lethal metabolic defect is complemented by the protein encoded by the functionally similar gene.

The method contemplates that the recombinant vector (the plasmid) is isolated from the surviving transformants using known method (Strathern, J.N. and Higgins, D.R. (1991). Plasmids are recovered from yeast into *Escherichia coli* shuttle vectors in: Guthrie, C. and Fink, G.R. Methods in Enzymology, Volume 194. Guide to yeast genetic and molecular Biology. Academic Press, San Diego, 319-329) and the cDNA or genomic DNA is analyzed using DNA-analysis methods such as DNA sequencing. (Sanger et al. (1977), Proc. Natl. Acad. Sci. USA 74: 5463-5467)

The method contemplates that essential *S.cerevisiae* genes may be used for the identification of functionally similar genes and/or genes homologous in sequence in other mycetes, especially essential genes functionally similar and/or homologous in sequence in mycetes pathogenic to human, animal and plants. For this purpose for example mycetes of the classes phycomycetes or eumycetes may be used, in particular the subclasses basidiomycetes, ascomycetes, especially mehliscomycetales (yeast) and plectascales (mould fungus) and gymnascales (skin and hair fungus) or of the class of hyphomycetes, in particular the subclasses conidiosporales (skin fungus) and thallosporales (budding or gemmiparous fungus), among which particularly the species mucor, rhizopus, coccidioides, paracoccidioides (blastomyces brasiliensis), endomyces (blastomyces), aspergillus, penicilium (scopulariopsis), trichophyton (ctenomyces), epidermophyton, microsporon, piedraia,

hermodendron, phialophora, sporotrichon, cryptococcus, candida, geotrichum and trichosporon.

Of particular interest is the use of Candida Spp. especially Candida albicans, Candida glabrata, Aspergillus Spp., especially Aspergillus fumigatus, Coccidioides immitis, Cryptococcus neoformans, Histoplasma capsulatum, Blastomyces dermatitidis, Paracoccidioides brasiliensis and Sporothrix schenckii.

The method contemplates that essential mycete genes are used to identify substances which may inhibit partially or totally the functional expression of these essential genes and/or the functional activity of the encoded proteins. Substances may be identified in this fashion, which inhibit mycetes growth and which can be used as antimycotics, for example in the preparation of drugs.

A particular feature of this method is that essential mycete genes or the corresponding encoded proteins are used as targets for the screening of the substances. The method contemplates that essential *S. cerevisiae* genes as well as functionally similar genes and/or genes homologous in sequence of other mycetes or the corresponding encoded proteins may be used as targets.

According to one embodiment of the screening method of the invention, mycetes cells are provided, which contain the essential gene used as target, and those cells are incubated with the substance to be tested. By this way, the growth inhibitory effect of this substance with respect to the essential target gene is determined.

The mycetes cells which express the essential target gene to a different degree are used, and these cells are then incubated with the substance to be tested and the growth inhibitory effect of this substance is determined.

The method includes the use of two or more mycetes cells, or strains derived therefrom, which differ in that they express the essential target gene to a different degree.

For example, two, three, four, five, ten or more mycetes cells or the corresponding mycetes strains may be comparatively analysed with respect to the growth

inhibitory effect of a substance used in a defined concentration. Through such concentration series, antimycotic substances may be distinguished from cytotoxic or inactive substances.

A particular embodiment of the method includes the use of haploid mycetes cells/ strains for the screening, especially haploid *S.cerevisiae* cells/ strains.

The method contemplates the integration of the essential gene selected as a target in a suitable expression vector.

As expression vectors *E.coli*/*S.cerevisiae* shuttle vectors are for example suitable. Especially vectors differing in their copy number per cell may be used. Therefore, one may use vectors, which are present in the transformed *S.cerevisiae* cells in a high copy number, or one can also use those with a low copy number. One embodiment comprises the use of expression vectors which allow the integration of the target gene in the *S.cerevisiae* genome.

For example the vectors pRS423, pRS424, pRS425, pRS426, pRS313, pRS314, pRS315, pRS316, pRS303, pRS304, pRS305, pRS306 (Sikorki and Hieter, 1989; Christianson et al. 1992) are appropriate as expression vectors.

The vectors of the series pRS423 - pRS426 are present in a high copy number, about 50 - 100 copies/ cell. On the contrary, the vectors of the series pRS313 - pRS316 are present in a low copy number (1 - 2 copies / cell). When expression vectors from these two series are used, then the target gene is present as an extrachromosomal copy. Using the vector of the series pRS303 - pRS306 allows the integration of the target genes into the genome. Using these three different expression vector types allows a gradual expression of the studied functionally similar essential gene.

The method includes that the growth inhibitory effect of substances with respect to mycetes cells/strains is comparatively determined using expression vectors differing for instance in the copy number of the vector/ cell.

Such cells may express the essential target gene to a different degree and may exhibit a graduated reaction with respect to the substance.

The method includes also, that a target gene expression of different strength is obtained in different mycetes cells (regulated overexpression) by insertion of the target gene in the expression vector between specific selected *S.cerevisiae* promoters and terminators. *S.cerevisiae* promoters which are constitutively expressed, but with different strength, are suitable. Examples for such promoters are native promoters of *S.cerevisiae* genes MET25, PGK1, TPI1, TDH3, ADH1, URA3, TRP1, as well as corresponding derivatives therefrom, for example promoter derivatives without specific activator and/or repressor sequences.

Regulated promoters are also appropriate for the graduated over-expression of the target gene. The native promoters of the GAL1 genes and/or corresponding derivatives thereof, for example promoters, in which different UAS elements have been eliminated. (GALS, GALL; Mumberg et al. (1994) Nucleic Acids Research 22: 5767-5768) as well as promoters of gluconeogenic genes, for example the promoters FBP1, PCK1, ICL1, or parts thereof, for example their activator- (UAS1 or UAS2) or repressor- (URS) sequences are used in corresponding non activable and/or non repressible test promoters (Schüller et al. (1992) EMBO J. 11: 107-114) Guarante et al. (1984) Cell 36: 503-511; Niederacher et al. (1992) Curr. Genet. 22: 363-370; Proft et al. (1995) Mol. Gen. Genet. 246: 367-373).

In the expression vector terminator for example the terminator sequence of *S.cerevisiae* genes MET25, PGK1, TPI1, TDH3, ADH1, URA3 may be used.

The method includes that by the use of cleverly selected expression vector types and/or the preparation of suitable expression vectors, eventually using promoters of different strength and differently regulated promoters, a series of expression vectors may be constructed, all containing the same target gene, but differing in that they express the target gene to a different extent.

The method includes the transformation of the expression vector in haploid wild-type cells of *S.cerevisiae*. The thus obtained *S.cerevisiae* cells/strains are cultivated in liquid medium and incubated in the presence of different concentrations of the tested substance and the effect of this substance on the growth behaviour of the cells/strains expressing the target gene to a different degree is comparatively analysed. The method also includes that haploid *S.cerevisiae* cells/strains, transformed using the respective expression vector type without target gene, are used as a reference.

The method includes that the screening of the substances can be carried out in different media using regulated promoters, especially GAL1 promoter and its derivatives (GALS and GALL), since the expression degree may be largely influenced by the choice of the respective medium. Thus, the expression degree of the GAL1 promoter decreases in the following fashion: 2 % galactose > 1 % galactose + 1 % glucose > 2 % glycerine > 2 % glucose.

The effect of the substances inhibiting the growth of wild-type cells of *S.cerevisiae*, may be partially or totally compensated by the overexpression of the functionally similar gene of another mycete species.

According to one embodiment, the method for screening antimycotic substances is carried out in vitro by contact of an essential or functionally similar gene or the corresponding encoded protein with the substance to be tested and determination of the effect of the substance on the target. Any in vitro test appropriate for determining the interaction of two molecules, such as a hybridization test or a functional test, can be used (e.g. enzymatic tests which are described in details in Bergmeyer H.U., Methods of Enzymatic Analysis, VCH Publishers). If the screening is carried out using the encoded protein as the target, then the corresponding essential gene is inserted by any suitable method known in the art, such as PCR amplification using a set of primers containing appropriate restriction sites, (Current Protocol in Molecular Biology, John Wiley and Sons, Inc) into an expression system, such

as *E. coli*, Baculovirus, or yeast, and the expressed protein is then completely or partially purified by a method known in the art. Any purification method appropriate for the purification of expressed proteins, such as affinity chromatography can be used. If the target protein function is known, a functional test can then be carried out in which the effect of the antimycotic substance on the protein function is determined. If the protein function is unknown, substances which can interact with the target protein, e.g. which bind to the encoded protein, can be tested. In such a case a test such as protection of the target protein from enzymatic digestion by appropriate enzymes can be used.

The method also includes the identification of genes which are functionally similar and/or homologous in sequence to essential *S.cerevisiae* genes from humans, animals or plants. The corresponding human, animal or plant genes may optionally be used as target genes in the method in order to test if antimycotic substances exhibit an effect on these target genes.

A particular advantage of the method is that in this way substances may be identified which efficiently inhibit mycetes growth and also the influence of these substances on corresponding functionally similar genes and/or genes homologous in sequence to essential *S.cerevisiae* genes from human, animal or plants may be determined.

The method includes also the possibility to check the existence of functionally similar genes and/or human, animal or plant genes homologous in sequence to the corresponding essential mycete genes, for example by checking homology of the identified essential mycete genes or parts thereof with human, animal or plant sequence genes available in data banks. In this way, it is possible to select at an early stage from the identified essential mycete genes, depending on the aim, those for which no functionally similar gene and/or no human gene homologous in sequence exist, for example.

Thereby, the method offers a plurality of possibilities to identify selectively substances with antimycotic effects, with no harmful effect on human beings.

For example, it is possible to identify substances usable for the preparation of drugs for the treatment of mycosis or prophylaxis in immunodepression states. These substances may be used for example for the manufacture of drugs usable for the treatment of mycotic infections, which occur during diseases like Aids or Diabetes. Substances which may be used for the fabrication of fungicides, especially of fungicides which are harmless for humans and animals, can also be identified.

Furthermore, the method offers the possibility to identify antimycotic substances, which selectively inhibit growth of specific mycete species only.

The screening method is particularly advantageous inasmuch as it is sufficient to know whether the genes are essential, one does not need any additional information regarding the function of the essential genes or the function of the encoded proteins. In addition, it is particularly advantageous for the identification of functionally similar genes to essential *S.cerevisiae* gene, in other mycetes where the DNA sequence is not available for many of these genes.

Examples

Example 1 :

Preparation of a deletion cassette for ORF YML114c, by the classical method using PCR (modified classical method)

1) Construction of the plasmids

pBluescript®KS+ vector (Stratagene; the sequence of which is available on Genbank®X52327) is used as the starting vector for the preparation of the other plasmids.

The vector is cleaved with NotI and the single-stranded ends are subsequently eliminated by incubation with Mung Bean exonuclease. By religation of DNA fragments, the pKS+ΔNotI vector is thus obtained

(corresponding to the pBluescript@KS+ without the NotI restriction site).

pKS+ΔNotI is cleaved with PstI and BamHI and the DNA oligonucleotide, synthesized from the pK3/pK4 primer pair described below, is ligated in the opened plasmid. The pKS+neu plasmid thus prepared contains between PstI and BamHI restriction sites, the following novel restriction sites NotI, StuI, SfiI and NcoI i.e. PstI-NotI-StuI-SfiI-NcoI-BamHI.

5'-GCGGCCGCAAGGCCTCCATGGCCG-3' PK3

5'-GATCCGGCCATGGAGGCCTTGCGGCCGCTGCA-3' PK4

The URA3 gene of *S.cerevisiae* is amplified via PCR, by use of the primer-pair PK9 and PK10, described below, and an Ycplac33 vector DNA (Gietz, R. D. and Sugino, A. (1988) Gene 74: 527-534) as matrix. The amplified DNA is cleaved with BamHI and NotI and subsequently inserted in pKS+neu which has been cleaved by BamHI and NotI. The plasmid thus obtained is named pPK9/10.

..NotI..

5'-ATCTGCAGCGGCCGCAAACATGAGAATTGGGTAATAACTG-3' PK9

PstI

..SfiI..

5'-ATGGATCCGGCCATGGAGGCCTTCAAGAAATTAGCTTTTCAATTCATC-3'

BamHI

PK10

2) Preparation of the deletion cassette

The 5'-region of ORF YML114c was amplified by PCR using genomic DNA of *S.cerevisiae* as template and both primers YML114c-Asp718 and YLM114c-EcoRI, described below.

YML114c-Asp718: 5'-GCTGGTACCCGTCGGTCTCTTTACC-3'

YLM114c-EcoRI: 5'-TTGGAATTCATTGCCCTTTATGAGTCC-3'

The PCR fragment was subsequently cut with the restriction enzymes Asp718 and EcoRI. The resulting 613BP fragment was inserted in pPK9/10 linearized with Asp718 and EcoRI generating plasmid pYML114c-A.

The 3' region of ORF YML114c was amplified by PCR using genomic DNA of *S.cerevisiae* as template and both primers YML114c-BamHI and YML114c-SacI, described below.

YML114c-BamHI: 5'-ATCGGATCCGCCAACAATGACAGCG-3'

YML114c-SacI: 5'-GTTGAGCTCTGAGCGTTTGTCTTG-3'

The PCR fragment was subsequently cut with BamHI and SacI. The resulting 535bp fragment was inserted in plasmid pYML114c-A linearized with BamHI and SacI generating pYML114c-B.

This latter plasmid was used for transformation of *S.cerevisiae* after linearization with Asp178 and SacI.

Examples 2-90: Construction of deletion cassettes for the remaining genes listed in table 1

Using the method disclosed in example 1, the deletion cassettes of each of the essential genes can be constructed using as primers those disclosed in table 2.

Example 91:

S.cerevisiae cells from strain CEN.PK2 are transformed using each about 5 μ g DNA of the linear deletion cassette of examples 1 to 90 according to known methods (Gietz et al. 1992; Güldener et al. 1996). The transformation reaction medium is plated on plates on the corresponding selective media. In this manner, the transformants are selected, in which homologous recombination occurred, since only these cells can grow under these modified conditions.

The recombinant cells were submitted to a tetrad analysis in the following conditions: Reduction division (meiosis) was induced in the heterozygote mutant strain using known methods (Guthrie C. and Fink, G.R. (1991) Methods in Enzymology, Vol 194, Academic Press, San Diego). The resulting asci were submitted to partial enzymatic digestion with zymolyase to digest the ascospore wall and separated using a micromanipulator (SINGER Instruments). This analysis demonstrated that all the above-mentioned 90 genes are essential for the growth of *S.cerevisiae*.

The present invention also applies more specifically to the following genes: YML114c, YLR186w, YLR215c, YLR222c, YLR243w, YLR272c, YLR275w, YLR276c,

YLR317w, YLR359w, YLR373c, YLR424w, YLR437c, YLR440c,
YML023c, YML049c, YML077w, YML093w, YML127w, YMR032w,
YMF093w, YMF121c, YMR185w, YMR212c, YMF213w, YMR218c,
YMF281w, YMF288w, YMF290c, YMR211w, YMF049c, YMF134w,
YDR196c, YDR299w, YDR365c, YDR396w, YDR407c, YDR416w,
YDR449c, YDR472w, YDR499w, YDR141c, YDR324c, YDR325w,
YDR398w, YDR246w, YDR236c, YDR361c, YDR367w, YDR339c,
YDR413c, YDR429c, YDR468c, YDR489w, YDR527w, YDR288w,
YDR201w, YDR434w, YDR181c, YDR531w, YPL126w, YPL093w,
YPL063w, YPL024w, YPL020c, YPL012w, YPL007c, YPL233w,
YPL146c, YIL001c, YIL083c, YIL019w, YIL104c, YPL024c,
YPR003c, YPR027w, YPR042w, YPR010w, YPR048w, YPR072w,
YPR032c, YPR085c, YPR105c, YPR112c, YPR137w, YPR143w,
YPR144c and YPR169w.

TABLE 1: ESSENTIAL GENES

Systematic ORF name	aa	deleted nucleotides	deleted amino acids	comments
YMR049C	807	18-2277	6-759	weak similarity to A.thaliana PRL1 protein
YMR134W	237	5-740	2-237	hypothetical protein
YDR196C	241	174-543	59-181	similarity to C.elegans hypothetical protein T05G5.5
YDR299W	534	41-1560	14-520	hypothetical protein; nuclear localization (see http://paella.med.yale.edu/YGAC/genes/localization.html)
YDR365C	628	45-1384	16-462	weak similarity to Streptococcus M protein
YDR396W	166	141-460	48-154	hypothetical protein
YDR407C	1289	48-3810	17-1270	weak similarity to Myolp
YDR416W	859	151-2540	51-847	synthetic lethal with CDC40
YDR449C	440	21-1270	8-424	hypothetical protein
YDR472W	283	41-810	14-270	similarity to P.falciparum 41-2 protein antigen
YDR499W	747	41-2100	14-700	weak similarity to hypothetical C.elegans protein, M.genitalium peptide chain release factor 1 and YJL149W
YDR141C	1698	51-4850	18-1617	hypothetical protein
YDR324C	717	79-2288	27-763	weak similarity to beta transducin from S. pombe and other WD-40 repeat containing proteins
YDR325W	1051	110-3109	37-1037	hypothetical protein
YDR398W	643	41-1880	14-627	similarity to human KIAA0007 gene
YDR246W	219	41-580	14-194	hypothetical protein
YDR236C	218	30-489	11-163	similarity to hypothetical A. thaliana protein
YDR361C	283	43-812	15-271	hypothetical protein
YDR367W	221	354-643	119-215	hypothetical protein
YDR339C	189	40-529	14-177	weak similarity to hypothetical protein YOR004w
YDR413C	191	81-500	28-167	weak similarity to NADH dehydrogenase; or YDR412w
YDR429C	274	86-645	29-215	TIF35; Vornlocher, H.-P., Hanachi, P. and Hershey, J.W.B. Cloning and Characterization of the Two Large Subunits of Yeast Translation Initiation Factor eIF3. Unpublished; translation initiation factor eIF3 (p33 subunit)

Systematic ORF name	aa	deleted nucleotides	deleted amino acids	comments
YDR468C	224	123-602	42-201	TLG1; member of the syntaxin family of t-SNAREs; tlg mutants seems to have a defect in the retrieval pathway to the TGN; viable
YDR489W	294	131-630	44-210	hypothetical protein
YDR527W	439	41-1260	14-420	weak similarity to Plasmodium yoelii rhopty protein, or YDR526C
YDR288W	303	41-800	14-267	hypothetical protein
YDR201W	165	130-319	43-107	hypothetical protein
YDR434W	534	41-1400	13-467	Similarity to S.pombe hypothetical protein
YDR181C	481	194-1323	65-441	SAS4 (viable); involved in silencing at telomeres
YDR531W	367	41-850	14-284	Similarity to hypothetical A. thaliana and C. elegans proteins
YLR186W	252	4-750	2-250	strong similarity to S. pombe hypothetical protein C18G6.07C
YLR215C	360	31-970	11-324	Similarity to rat cell cycle progression related D123 protein; there are few domains identical to the D123 protein
YLR222C	817	8-2378	3-793	similarity to Dip2p
YLR243W	272	41-700	14-234	strong similarity to YOR262w
YLR272C	1176	15-3384	6-1128	similarity to hypothetical human ORF
YLR275W	110	32-360	11-90	contains intron; strong similarity to human snRNPchain D2 involved in systemic lupus erythematosus; identified as part of the U1 complex by mass spectrometrie, PNAS 94: 385-390 (1997) Neubauer G. et al.
YLR276C	594	44-1733	15-578	similarity to RNA helicases; identified as part of the U1 complex by mass spectrometrie, PNAS 94: 385-390 (1997) Neubauer G. et al.
YLR317W	144	4-403	2-135	-
YLR359W	482	120-1399	41-467	strong similarity to adenylosuccinate lyase
YLR373C	901	14-2693	5-898	similarity to hypothetical protein YGR071c

Systematic ORF name	aa	deleted nucleotides	deleted amino acids	comments
YLR424w	708	109-2098	37-700	weak similarity to Stulp
YLR437c	133	7-376	3-126	-
YLR440c	709	18-1978	7-660	-
YML023c	556	81-1640	28-547	weak similarity to Nmd2p
YML049c	1361	258-3967	87-1323	weak similarity to monkey UV-damaged DNA-binding protein
YML077w	159	41-390	13-130	-
YML093w	899	29-2642	9-881	similarity to P falciparum liver stage antigen LSA-1
YML114c	510	11-1410	3-470	-
YML127w	581	65-1704	21-568	weak similarity to Loslp
YMR032w	669	46-2002	15-668	weak similarity to S. pombe cdc15
YMR093w	513	41-1300	13-434	weak similarity to Pwp2p
YMR131c	511	11-1410	3-470	similarity to human retinoblastoma-binding protein
YMR185w	981	65-2914	21-972	-
YMR212c	782	56-2287	18-763	weak similarity to myosin
YMR213w	590	58-1533	19-511	similarity to S. pombe putative transcription factor cdc5
YMR218c	1102	157-3253	52-1085	-
YMR281w	304	26-760	8-254	-
YMR288w	971	131-2670	43-890	strong similarity to S. pombe und C. elegans proteins
YMR290c	505	11-1471	3-491	strong similarity to Myc-regulated DEAD box protein
YMR211w	475	72-1341	25-447	weak similarity to beta tubulins
YFL024c	832	47-2406	16-802	EPL1 (viable); weak similarity to YMR164c and Gal1p
YFR003c	155	106-315	36-105	hypothetical protein
YFR027w	281	40-649	14-217	hypothetical protein
YFR042w	200	344-873	115-291	hypothetical protein
YIL091c	721	44-1953	15-651	weak similarity to spt5p
YIL083c	365	46-1005	16-335	hypothetical protein
YIL019w	346	81-1000	27-334	hypothetical protein
YIL109c	926	42-2721	14-907	SEC24 (lethal); component of COPII coat of ER-Golgi vesicles

Systematic ORF name	aa	deleted nucleotides	deleted amino acids	comments
YIL104C	507	133-1082	45-361	similarity to hypothetical S. pombe protein
YIR010W	576	41-1500	14-500	hypothetical protein
YIR015W	144	85-274	29-92	hypothetical protein
YPL126W	896	41-2700	14-900	weak similarity to fruit fly TFIID subunit p85
YPL093W	647	151-1900	51-634	similarity to M.jannaschii GTP-binding protein, GTP1/OBG-family, weak similarity to other GTP-binding proteins
YPL063W	476	126-1385	42-462	similarity to hypothetical protein YLR019W, YLL010C and S.pombe hypothetical protein SPAC2F7.02C
YPL024W	241	41-550	14-184	NCE4 (viable); negative regulator of CTS1 expression
YPL020C	621	44-1813	15-605	weak similarity to Smt4p
YPL012W	1228	41-3630	14-1210	hypothetical protein
YPL007C	588	55-1614	19-538	hypothetical protein
YPL233W	216	41-610	14-204	hypothetical protein
YPL146C	455	46-1325	16-442	weak similarity to myosin heavy chain proteins
YPR048W	623	41-1650	14-550	similarity to M.domestica NADPH--ferrihemoprotein reductase and mammalian nitric-oxide synthases
YPR072W	560	42-1541	14-514	NOT5 (viable); component of the NOT protein complex
YPR082C	143	140-279	47-93	weak similarity to Ypk1p
YPR085C	448	277-1166	93-389	hypothetical protein
YPR105C	861	74-2543	25-848	hypothetical protein
YPR112C	887	52-2521	18-841	similarity to RNA-binding proteins
YPR137W	573	41-1680	14-560	weak similarity to Taf90p
YPR143W	250	41-710	14-237	hypothetical protein
YPR144C	552	107 1616	36-539	similarity to YDR060W and C.elegans hypothetical protein
YPR169W	514	201-1490	201-1490	hypothetical protein

TABLE 2: Primers used for gene deletions

Gene deletions on chromosome 13	
Name	Sequence 5'-3'
YDR472w-S1	ATG TCT CAA AGA ATA ATT CAA CCA AGC GCA TCT GAC CAA CCA GCT GAA GCT TCG TAC GC
YDR472w-S2	AGC CAA ATC TCA AAC CTT CCC TGT CAA GCA CTT GCC TGT CGC ATA GGC CAC TAG TGG ATG TG
YDR499w-S1	ATG AGA CGA GAA ACG GTG GGT GAA TTT TCT TCA GAT GAC GCA GCT GAA GCT TCG TAC GC
YDR499w-S2	CGT ACT TTA CTT GCA TTA TTC TCC CCG TTC TTT TAT TCA AGC ATA GGC CAC TAG TGG ATG TG
YMR049c-S1	CAG ACT ATT GAT TAC TTT ATG ACC GGT TAG TTT CTT TAG TCA GCT GAA GCT TCG TAC GC
YMR049c-S2	TCT GTT CTA ACA TAA CTA GGT CAA TGA TGG CTA AGA ACA AGC ATA GGC CAC TAG TGG ATC TG
YMR134w-S1	GCA AAG TGT GGT ATA GAA AAA GAA CCA AAG GCC GGT ATG TCA GCT GAA GCT TCG TAC GC
YMR134w-S2	TGT GTG TGT GCC TAC CTG CAT GTA TGC ATT TAG CAA TTG AGC ATA GGC CAC TAG TGG ATC TG
YML023c-S1	CAC GCA ATG GTG CAC ATT ATT TTG TTG AAC TCA CTG AGA ACA GCT GAA GCT TCG TAC GC
YML023c-S2	ATT AGT TAC TTA TTC TAT AAT TAC ACT TTT ATC ATG AAC GGC ATA GGC CAC TAG TGG ATC TG
YML049c-S1	AAT TCC TGC TCA TTC AAG GAA AGT CTC AGG AAA TTT TCA CCA GCT GAA GCT TCG TAC GC
YML049c-S2	ACT CCT GCA TCG GAC ACT TCG TCG ATC TGG AAG CAG GGT CGC ATA GGC CAC TAG TGG ATC TG
YML077w-S1	ATG GGG ATA TAT TCA TTT TGG ATC TTT GAT AGG CAT TGT ACA GCT GAA GCT TCG TAC GC
YML077w-S2	TTC TAT TGG TGA TCT TTC TTG TCC CTT GAC CTC TCA TTT CGC ATA GGC CAC TAG TGG ATC TG
YML093w-S1	GCT AAC TTA AAT ATG GCA AAA AAG AAA TCT AAG AGC AGA TCA GCT GAA GCT TCG TAC GC
YML093w-S2	CAA AGG ATC AAT AAC TTG GCC TGG CTT AGT CAT GAT TCT CGC ATA GGC CAC TAG TGG ATC TG
YML114c-S1	AAC GTG TAA TTG AGG GAC TCA TAA AGG GCA ATG ACT TCC ACA GCT GAA GCT TCG TAC GC
YML114c-S2	GAC TTG TAG TAG CAT CGA TAT TGG TTG TGT TAT GTG CTA CGC ATA GGC CAC TAG TGG ATC TG
YML127w-S1	CCG CTA AAT GGT ACT CCA GTA AGC GAG GCA CCC GCC ACA ACA GCT GAA GCT TCG TAC GC
YML127w-S2	ATA ACC CCG ACG TGT TTT CCA TGT ATT CAG ACA ATG CTA AGC ATA GGC CAC TAG TGG ATC TG

Gene deletions on chromosome 13												
Name	Sequence 5'-3'											
YMR032w-S1	CTA	CAG	TTA	TGA	AGC	TTG	TTT	TTG	GGA	CCC	AAA	CGA
	CAA	TCA	GCT	GAA	GCT	TCG	TAC	GC				
YMR032w-S2	CAG	AAA	ACT	AGT	AAA	ATT	GAT	ATA	CAT	CGA	GAT	CAA
	AGA	CGC	ATA	GGC	CAC	TAG	TGG	ATC	TG			
YMR093w-S1	ATG	TCG	ACT	GCT	AGG	CCT	AGA	ATA	ATC	ACT	TCG	AAG
	GCT	CCA	GCT	GAA	GCT	TCG	TAC	GC				
YMR093w-S2	AAG	CAC	CAA	TTC	AGT	AGC	GGC	TCT	AAT	GTA	GAT	TCA
	TCT	CGC	ATA	GGC	CAC	TAG	TGG	ATC	TG			
YMR131c-S1	CTT	TAA	CTT	CCT	TTT	GCC	AGT	GAA	CAA	ACA	ATA	ATT
	GTG	GCA	GCT	GAA	GCT	TCG	TAC	GC				
YMR131c-S2	GGT	CTA	TCG	AGG	TCA	ACG	AGG	AAC	AAG	ATA	GAG	TGG
	TCT	CGC	ATA	GGC	CAC	TAG	TGG	ATC	TG			
YMR185w-S1	ATC	AAC	ATA	CAC	GAT	ATA	TTG	AAT	ACA	AGA	CCG	AAG
	CTC	ACA	GCT	GAA	GCT	TCG	TAC	GC				
YMR185w-S2	GTA	ATG	GGT	TAT	AAA	CTA	TCT	AGT	ACG	GTT	AAA	AGC
	TTG	TGC	ATA	GGC	CAC	TAG	TGG	ATC	TG			
YMR212c-S1	CCT	CTT	GAA	CTT	AAA	GAA	TGT	AAA	TCT	TCA	TTT	GCG
	TCT	TCA	GCT	GAA	GCT	TCG	TAC	GC				
YMR212c-S2	CGG	ATG	ATG	TTC	ACA	CCA	AAA	CAT	CAG	AAA	CTG	GTC
	AAT	CGC	ATA	GGC	CAC	TAG	TGG	ATC	TG			
YMR213w-S1	ATA	CGT	GAA	AGG	CGG	TGT	ATG	GAC	CAA	TGT	GGA	GGA
	TCA	GCA	GCT	GAA	GCT	TCG	TAC	GC				
YMR213w-S2	GCT	GTA	ACT	GTT	CAA	TAG	ACT	CCA	CTT	TTG	ATT	GGA
	TCG	AGC	ATA	GGC	CAC	TAG	TGG	ATC	TG			
YMR218c-S1	GAC	TCA	AAT	GCA	TTA	GAG	TGA	TCA	ACT	CTA	CAA	CTT
	TTA	CCA	GCT	GAA	GCT	TCG	TAC	GC				
YMR218c-S2	GAA	GGC	ATT	TGA	CGG	AAC	TGT	ACG	AAC	GGT	TAA	CAG
	GCT	TGC	ATA	GGC	CAC	TAG	TGG	ATC	TG			
YMR281w-S1	CTG	AAG	AAA	AGT	TAA	ATG	AAG	ATG	TTG	AGG	CGT	ACA
	AAG	GCA	GCT	GAA	GCT	TCG	TAC	GC				
YMR281w-S2	AGT	ACG	TAT	TGT	GCA	TGT	GTA	TTC	ATA	AGT	GAA	AGC
	TTG	TGC	ATA	GGC	CAC	TAG	TGG	ATC	TG			
YMR288w-S1	GAA	AAC	CTG	CAG	AAA	GAA	GCT	GCA	CGT	ATT	GGT	GAG
	AAC	GCA	GCT	GAA	GCT	TCG	TAC	GC				
YMR288w-S2	CCA	AAC	CTT	CTA	AAA	TAC	GCA	TAA	TAG	CAT	GTG	GTG
	AAG	TGC	ATA	GGC	CAC	TAG	TGG	ATC	TG			
YMR290c-S1	TGA	GTT	TTA	CGT	CTT	TTG	GTA	TTT	GGC	GTT	TTT	CCA
	CTG	GCA	GCT	GAA	GCT	TCG	TAC	GC				
YMR290c-S2	GAT	AAG	CTG	AGC	AAT	ATT	AAC	AGG	AGA	AGT	ATG	GCT
	ACC	CGC	ATA	GGC	CAC	TAG	TGG	ATC	TG			
YMR211w-S1	AGA	GAG	CAA	ACC	ATT	TGA	CTA	CTC	AAT	TCT	TCA	ATA
	TAC	ACA	GCT	GAA	GCT	TCG	TAC	GC				
YMR211w-S2	ATT	TCA	ATC	ATC	TTA	CTC	CGT	GAA	TCA	GGT	TCG	GAA
	TGA	TGC	ATA	GGC	CAC	TAG	TGG	ATC	TG			

Gene deletions on chromosome 4	
Name	Sequence 5'-3'
YDR196c-S1	ATG CTT ATG ATC AAA TTG TGT TAT ACT TCA AGG ACA AAA TCA GCT GAA GCT TCG TAC GC
YDR196c-S2	TTT CAA TCT GTT CGT ATA AGT CAA CCA ATG TGC TGT TAT TGC ATA GGC CAC TAG TGG ATC TG
YDR299w-S1	ATG GAA AAA TCA CTA GCG GAT CAA ATT TCC GAT ATC GCC ACA GCT GAA GCT TCG TAC GC
YDR299w-S2	CAA AGA TTT GGA TAT CAT CGT TTT TAA CAG CCT CTA ATT CGC ATA GGC CAC TAG TGG ATC TG
YDR365c-S1	CTG GAG AGA ACC CAA AGA AGG AAG GTG TAG ATG CTA GGT TCA GCT GAA GCT TCG TAC GC
YDR365c-S2	TTA GTA TGC TTT TTA TTA ACA GAT TTC AAC TTG CTT TTC TGC ATA GGC CAC TAG TGG ATC TG
YDR396w-S1	CAG ATA CAC TAT TGT GGT GTA ATC TGG ACC TTG ACT GTC TCA GCT GAA GCT TCG TAC GC
YDR396w-S2	TAG AGA AAA CAC TGA ATG ATC TTA GCG ACC GTA CAA AAG AGC ATA GGC CAC TAG TGG ATC TG
YDR407c-S1	TTC TTA AGC ATT TCC CAA GCT ATG TTG GCC CAT CTA AGA TCA GCT GAA GCT TCG TAC GC
YDR407c-S2	AAT AAC AGA CAA GAT AAC GTT TTC AGA GTC GAA CTG GAT TGC ATA GGC CAC TAG TGG ATC TG
YDR416w-S1	ACT TAC ATG GAA AAG ATA TAT CGA GTA TTG GAA AGA GGA GCA GCT GAA GCT TCG TAC GC
YDR416w-S2	TCA AAT ATC TAG TTC TAT TTC ATC TGG ATT AAT CGA ATA TGC ATA GGC CAC TAG TGG ATC TG
YDR449c-S1	CAC ATC ACC GAT TTC TAA TAA TGT CGA AGA CAA GAT ACT ACA GCT GAA GCT TCG TAC GC
YDR449c-S2	ATA ATT AAA TCT AGA ATT TTA TAC CTA GGA TCA TCT TCT GGC ATA GGC CAC TAG TGG ATC TG
YDR141c-S1	TTC GTA ATC TTT GAA TTC TGC GAT TTC ATC TAC CAG CGC GCA GCT GAA GCT TCG TAC GC
YDR141c-S2	CAC TAA AGC CCC TTA CAA TTG ACT CAA ATA ATA AAC AAC TGC ATA GGC CAC TAG TGG ATC TG
YDR324c-S1	AAG AAG CCT GAA AAT ACG AAA CAA ACC GGT GAA GAT GAC CCA GCT GAA GCT TCG TAC GC
YDR324c-S2	AAA CACTAA CTT TGG TTG AAT AAA CGC CTT TTG TTT GGA GGC ATA GGC CAC TAG TGG ATC TG
YDR325w-S1	GAC ATT AAT ACG AAA ATC TTT AAC TCA GTT GCT GAA GTA TCA GCT GAA GCT TCG TAC GC
YDR325w-S2	ACC TCG CTG AAA GAC TCT GAA TCC TTA TCT TCT TCA TCT AGC ATA GGC CAC TAG TGG ATC TG
YDR398w-S1	ATG GAT TCT CCT GTT CTA CAG TCC GCT TAT GAC CCA TCA GCA GCT GAA GCT TCG TAC GC
YDR398w-S2	AAC GTC ACT ATA TCC GGC TTC CTC CTC GCC GTC GCT CTG CGC ATA GGC CAC TAG TGG ATC TG

Gene deletions on chromosome 4	
Name	Sequence 5'-3'
YDR246w-S1	ATG GCC ATC GAA ACA ATA CTT GTA ATA AAC AAA TCA GGC GCA GCT GAA GCT TCG TAC GC
YDR246w-S2	AAC AGG TTA GAT CTT ATA GGC ATT TCC ATT GAG TAA GAT GGC ATA GGC CAC TAG TGG ATC TG
YDR236c-S1	CTA AAA TAT TGA ACT TGA CCC TGG CCC CAT AAA AAT CAT TCA GCT GAA GCT TCG TAC GC
YDR236c-S2	TTG AAG TGT TGA TGT TTACGT GGA CTA TTT ATG TTT CGT TGC ATA GGC CAC TAG TGG ATC TG
YDR361c-S2	TTA CCA AGT GGA AAT TTC TGT TTC CAA TTC ATC GAT ACT TGC ATA GGC CAC TAG TGG ATC TG
YDR361c-S1	GGT TCA AGC TAT CAA ATT AAA TGA TTT AAA AAA TAG GAA GCA GCT GAA GCT TCG TAC GC
YDR367w-S1	ATC TGC GTA CTT TAT ACA ATC GAT ACC ATT TCC ACT TGT TCA GCT GAA GCT TCG TAC GC
YDR367w-S2	GTT TTG TTC TAC GTC ATC CCT ATC AAC TAA ATA TTT GGG GGC ATA GGC CAC TAG TGG ATC TG
YDR339c-S1	TAT GGG TAA AGC TAA GAA AAC AAG AAA GTT TGG CCT CGT ACA GCT GAA GCT TCG TAC GC
YDR339c-S2	TAA AAG ACA TCT GGC AAT TTT TCA ATG ACG TAT GCG TGA CGC ATA GGC CAC TAG TGG ATC TG
YDR413c-S1	TTC TTT GGT TTA TTC TTC GTT CAT TTT TGG TCA AAT ATC TCA GCT GAA GCT TCG TAC GC
YDR413c-S2	ACA AAA GAA AGC ACA AGA GTT TAT TAA GGA GCA GGA AAG GGC ATA GGC CAC TAG TGG ATC TG
YDR429c-S1	TCT AGA TCT ATC ATT ACA TAC AAG ATT GAA GAC GGT GTC ACA GCT GAA GCT TCG TAC GC
YDR429c-S2	TTT CTT TGT TTC TAA CGA CAG AAA CTC TTG GAA TGG GTG CGC ATA GGC CAC TAG TGG ATC TG
YDR468c-S1	GTC ACA ATA CTG CTG GTG ATG ACG ATC AAG AGG AGG AAA TCA GCT GAA GCT TCG TAC GC
YDR468c-S2	CAA GAC GAC AAT AAG AAG TCC TAT ACA ACA ATC GTC GTA TGC ATA GGC CAC TAG TGG ATC TG
YDR489w-S1	ACT ACC CAC AGA GAT GCA AAT ACA ATA GTG GGT TCG TCC TCA GCT GAA GCT TCG TAC GC
YDR489w-S2	AGT CGG GCT CAT CTA TCA TGT TTA CGC TAC CTT CTG TAT CGC ATA GGC CAC TAG TGG ATC TG
YDR527w-S1	ATG GAC TTA CTG GGC GAT ATA GTG GAG AAA GAT ACA TCT GCA GCT GAA GCT TCG TAC GC
YDR527w-S2	CCC CAC CGC CTT GTT TCC ATA ACC AAA GTG CAT CAA TAG CGC ATA GGC CAC TAG TGG ATC TG
YDR288w-S1	ATG AGT TCT ATA GAT AAT GAC AGC GAT GTG GAT TTA ACA GCA GCT GAA GCT TCG TAC GC
YDR288w-S2	GCC CAT GAT TTC TTG CAC CAA TTT TTC AAG AGA CTC TAG TGC ATA GGC CAC TAG TGG ATC TG

Gene deletions on chromosome 4	
Name	Sequence 5'-3'
YDR201w-S1	CCC ATG TCT GGA CTA TTC AGA GCA TCA TCG TCA TCC ATA CCA GCT GAA GCT TCG TAC GC
YDR201w-S2	AAA AGG GTT TTC CGT TTA GTT CCC GAA TAT GAT GTT GAA AGC ATA GGC CAC TAG TGG ATC TG
YDR434w-S1	ATG TCC AAT GCA AAT CTA AGA AAA TGG GTT GGT TTT TGC TCA GCT GAA GCT TCG TAC GC
YDR434w-S2	TAA AGG TAA ATA CAC AGC TAT CAT GTG CTC TTG TGG GAA GGC ATA GGC CAC TAG TGG ATC TG
YDR181c-S1	AGG ATA AAC CCA AAT GCT GGA CAT CTA AGG AAA TCT AAG TCA GCT GAA GCT TCG TAC GC
YDR181c-S2	TAG TTG GGT TTG AAT CGT TAT CAC GGG AGA ACA TTG CTT TGC ATA GGC CAC TAG TGG ATC TG
YDR531w-S1	ATG CCG CGA ATT ACT CAA GAG ATA TCT TAC AAT TGC GAT TCA GCT GAA GCT TCG TAC GC
YDR531w-S2	AAA TAA GCT ATT TGC CCA ATA TTG TTG GAG ATG GCG AAT AGC ATA GGC CAC TAG TGG ATC TG

Gene deletions on chromosome 12												
Name	Sequence 5'-3'											
YLR186w-S1	CTA	GTC	ACC	AAG	AAG	AAA	ACC	CGT	AAA	ATC	GTA	GGT
	CAT	GCA	GCT	GAA	GCT	TCG	TAC	GC				
YLR186w-S2	ATA	CAA	AGA	GGA	TGC	CAA	GTA	GAC	TTA	AAC	ACT	ATA
	AAA	TGC	ATA	GGC	CAC	TAG	TGG	ATC	TG			
YLR215c-S1	TTA	CTT	ATT	GAT	GTC	CTC	ACA	AGA	ATA	TAC	AAC	TTT
	TAT	ACA	GCT	GAA	GCT	TCG	TAC	GC				
YLR215c-S2	AGC	TCT	CGG	ATT	GCT	TCA	GGA	TTT	AAA	CTA	GCT	TCT
	ACG	AGC	ATA	GGC	CAC	TAG	TGG	ATC	TG			
YLR222c-S1	CTC	TCA	ACG	GTA	GTA	AGC	CAT	ACT	ACG	TAC	AAT	ATG
	GAT	CCA	GCT	GAA	GCT	TCG	TAC	GC				
YLR222c-S2	AAT	ATG	TAA	CTT	TGT	TCA	ACT	AAG	TTA	TCA	ACC	CTT
	GTG	AGC	ATA	GGC	CAC	TAG	TGG	ATC	TG			
YLR243w-S1	ATG	TCT	CGC	GTT	GGT	GTC	ATG	GTA	TTA	GGA	CCT	GCA
	GGT	GCA	GCT	GAA	GCT	TCG	TAC	GC				
YLR243w-S2	GAT	AAT	ATG	GTT	TCT	ATA	CTG	TCA	GGA	TTA	TTA	GAT
	TCC	AGC	ATA	GGC	CAC	TAG	TGG	ATC	TG			
YLR272c-S1	TTT	GGG	TCT	CGC	ACT	TTC	TCA	GTC	TTC	CAA	CTA	ATT
	TCT	CCA	GCT	GAA	GCT	TCG	TAC	GC				
YLR272c-S2	GGT	AAC	TGA	CTT	CGT	TAC	TTT	ATG	AGA	TGT	CCG	GCT
	TTA	GGC	ATA	GGC	CAC	TAG	TGG	ATC	TG			
YLR275w-S1	CCG	TTT	TAT	CAT	GTC	GTA	TGT	TTG	ATC	TTA	ACC	ATT
	TTT	ACA	GCT	GAA	GCT	TCG	TAC	GC				
YLR275w-S2	CAA	CGA	TAA	CTG	AAT	CAC	CTC	TTA	AGA	ATA	GTT	TAC
	TTA	TGC	ATA	GGC	CAC	TAG	TGG	ATC	TG			
YLR276c-S1	CTT	CAA	CGG	GTC	TAC	TTT	ACC	ATT	CTT	TGG	CTT	ACT
	GAC	TCA	GCT	GAA	GCT	TCG	TAC	GC				
YLR276c-S2	AGC	TAT	GAG	AAA	AAG	TCT	GTG	GAA	GGC	GCT	TAT	ATT
	GAC	GGC	ATA	GGC	CAC	TAG	TGG	ATC	TG			
YLR317w-S1	CTG	CCA	TCT	TCT	GCC	ACC	ACT	TTG	TCC	TTC	TTT	CTT
	GAT	GCA	GCT	GAA	GCT	TCG	TAC	GC				
YLR317w-S2	GAA	GTA	AAC	TAA	CTA	GTA	AAG	TAG	GCT	AAT	TCG	AAA
	CGA	TGC	ATA	GGC	CAC	TAG	TGG	ATC	TG			
YLR359w-S1	GGC	TAT	TGC	TGA	GAA	GGA	ATT	GGG	CTT	AAC	TGT	TGT
	TAC	ACA	GCT	GAA	GCT	TCG	TAC	GC				
YLR359w-S2	AAC	TTG	ACT	TGT	TCA	TCG	TTT	AGG	TAC	TTT	TGG	AAA
	GGT	TGC	ATA	GGC	CAC	TAG	TGG	ATC	TG			
YLR373c-S1	ACA	CAC	AGG	TAC	AGA	GTG	CTG	AAA	GAG	GAT	TGG	TGT
	TGC	CCA	GCT	GAA	GCT	TCG	TAC	GC				
YLR373c-S2	CAA	ACA	GAC	TTT	GTT	CCT	TTG	TAT	GTC	CTA	TGG	AAG
	ATA	CGC	ATA	GGC	CAC	TAG	TGG	ATC	TG			
YLR424w-S1	GAC	ATG	ACA	TAC	ACT	AAT	GAT	GCC	TTG	AAA	ACT	AGT
	AGC	GCA	GCT	GAA	GCT	TCG	TAC	GC				
YLR424w-S2	ATA	GGT	ACT	TTC	TAG	AGG	TCA	AGG	GCC	CAT	AAA	TAA
	ATT	GGC	ATA	GGC	CAC	TAG	TGG	ATC	TG			

Gene deletions on chromosome 12	
Name	Sequence 5'-3'
YLR437c-S1	ATT GTG CAA GTC TGT TAA AGT CTT CTC TTG GAT CCA TTA ACA GCT GAA GCT TCG TAC GC
YLR437c-S2	CAT CAC ACA CTA ATA CAG GAA CAA ACA AGA CTT AAT GGA CGC ATA GGC CAC TAG TGG ATC TG
YLR440c-S1	TTG CCA AGA AAA TTG CAG TAA AAA TGT TGG AAG AGC AAC TCA GCT GAA GCT TCG TAC GC
YLR440c-S2	GCT CCA ATT CTA GTG TGC TCC ATT GCG ATG TAA CAA TTT CGC ATA GGC CAC TAG TGG ATC TG

Gene deletions on chromosome 6	
Name	Sequence 5'-3'
YFL024c-S1	TGA TGA ATT TTT CTG GGT TAT AGA AGA GTT CTG TTT CGC TCA GCT GAA GCT TCG TAC GC
YFL024c-S2	ACA CCT TCA AAC GCT ATA GAG ATC AAT GAC GGT TCG CAT AGC ATA GGC CAC TAG TGG ATC TG
YFR003c-S1	TGT GGA AGA GGT TCC CGC AGT TTT GCA GCT TCG AGC AAC TCA GCT GAA GCT TCG TAC GC
YFR003c-S2	ATC TTC TTT GTC TAC GTT CGT TAA AGT CAA GAT CCT TCT CGC ATA GGC CAC TAG TGG ATC TG
YFR027w-S1	AAT GAA AGC TAG GAA ATC GCA GAG AAA AGC GGG CAG TAA ACA GCT GAA GCT TCG TAC GC
YFR027w-S2	AAT TTG GTT GCG ATA CCC AAC TTC CTT GCT GTC CTG CAC AGC ATA GGC CAC TAG TGG ATC TG
YFR042w-S1	AGT TTG CAC CAA TGG CAA TAT GCC TGT GAT AAA GAT AAG GCA GCT GAA GCT TCG TAC GC
YFR042w-S2	CAT GGA AGT TAT TTG GTT GCT TAG ATT CCA CGG GTT CAA AGC ATA GGC CAC TAG TGG ATC TG

Gene deletions on chromosome 9												
Name	Sequence 5'-3'											
YIL109c-S1	TGT	CTC	ATC	ACA	AGA	AAC	GTG	TTT	ACC	CAC	AAG	CTC
	AGC	TCA	GCT	GAA	GCT	TCG	TAC	GC				
YIL109c-S2	TCA	TGA	TTT	GTA	AGA	ATT	CTC	TGT	AAC	TTT	CGT	TAT
	TCA	AGC	ATA	GGC	CAC	TAG	TGG	ATC	TG			
YIL091c-S1	AGT	GAC	AGT	TCT	GTG	AGG	GAA	AAG	AAT	GAT	AAT	TTC
	CGT	GCA	GCT	GAA	GCT	TCG	TAC	GC				
YIL091c-S2	CAT	TGT	AAA	ATT	CAG	GAT	TGT	TTG	GAG	GCT	TAT	AAA
	AAA	CGC	ATA	GGC	CAC	TAG	TGG	ATC	TG			
YIL083c-S1	ACC	TCT	ACC	CGT	GCT	CAA	CAG	ACC	TCA	AAT	TCA	TAC
	GTC	TCA	GCT	GAA	GCT	TCG	TAC	GC				
YIL083c-S2	CGA	TGA	CTT	CTG	GGA	TTA	TCA	TCT	CTT	CAA	TGA	TAT
	GGT	GGC	ATA	GGC	CAC	TAG	TGG	ATC	TG			
YIL019w-S1	TTC	AAA	GAA	AAG	CTT	TTG	AAA	GTC	AGT	TCG	GAT	CTT
	TAG	ACA	GCT	GAA	GCT	TCG	TAC	GC				
YIL019w-S2	TAG	CGA	CGG	GAT	TTC	TTT	TTG	CCA	TTA	AAT	TTA	CCA
	CTC	CGC	ATA	GGC	CAC	TAG	TGG	ATC	TG			
YIL104c-S1	TCC	CCT	TAC	TAT	TTA	AGA	TTA	AGA	TTT	CCT	CAC	GAA
	TTA	ACA	GCT	GAA	GCT	TCG	TAC	GC				
YIL104c-S2	CCT	GAT	ACC	TGT	AAT	GAT	TGC	AAT	CTT	GAT	GAG	AGA
	GCT	GGC	ATA	GGC	CAC	TAG	TGG	ATC	TG			
YIR010w-S1	ATG	AGT	CTG	GAA	CCC	ACA	CAA	ACG	GTC	TCC	GGT	ACG
	CCG	CCA	GCT	GAA	GCT	TCG	TAC	GC				
YIR010w-S2	ACC	TTA	GCT	CAT	CGA	CTT	TTG	TTT	CTA	ACT	TTG	TCT
	CAA	CGC	ATA	GGC	CAC	TAG	TGG	ATC	TG			
YIR015w-S1	GCG	AAC	CAG	GAC	CAT	TTC	CAT	AGA	TTA	AAC	TAC	CTC
	TAC	CCA	GCT	GAA	GCT	TCG	TAC	GC				
YIR015w-S2	ATT	TCC	AGT	TTT	TTT	GGG	GTC	CAT	AAC	AAC	CGA	TGG
	CAT	TGC	ATA	GGC	CAC	TAG	TGG	ATC	TG			

Gene deletions on chromosome 16	
Name	Sequence 5'-3'
YPL233w-S1	ATG TCA CAA GGT CAG TCC AAA AAA CTG GAC GTA ACT GTT GCA GCT GAA GCT TCG TAC GC
YPL233w-S2	CAA TCC TCC TCC AGG AAG TCC ATT AAG CGC TTG ACC TTT TGC ATA GGC CAC TAG TGG ATC TG
YPL146c-S1	TCC AAC TAA TCT AACCAA GAA ACC ATC TCA ATA CAA ACA GCA GCT GAA GCT TCG TAC GC
YPL146c-S2	TTT GAA GTC CTT ATG TGT CCA CTT TTC AGT GAT TTT CTG CGC ATA GGC CAC TAG TGG ATC TG
YPL126w-S1	ATG ACG CAA TCC CTA GGT ATC GAA CAG TAT AAA CTG TCA GCA GCT GAA GCT TCG TAC GC
YPL126w-S2	TAT GTT AAT ACT TTC ATC ACA CGA TCA AAA AAT GTA TCC AGC ATA GGC CAC TAG TGG ATC TG
YPL093w-S1	CAA GAT TAC AAG AAT CAG AGCGTT CTA TAT GCG TAA AGT TCA GCT GAA GCT TCG TAC GC
YPL093w-S2	CGG AAA TCT GTC TTA CCG ACA CCA CGC TTA CCA CTG AAT AGC ATA GGC CAC TAG TGG ATC TG
YPL063w-S1	TTC AAG CAT CCA GAA GAC TTT TAA CAA GTT ATT CAA GTT TCA GCT GAA GCT TCG TAC GC
YPL063w-S2	GGA TTC AGC AAT CTT CTT CTT TTT CTT TTC CTC TTC AAA TGC ATA GGC CAC TAG TGG ATC TG
YPL024w-S1	ATG TCT TTT TCA TCT ATC TTA TCA CAG GAT ATC ACA GAT GCA GCT GAA GCT TCG TAC GC
YPL024w-S2	ACT TGT GAG TCC TTC AAT ATG AAA ACG CCC CTA TTG AAC AGC ATA GGC CAC TAG TGG ATC TG
YPL020c-S1	TCA GTT GAA GTA GAT AAG CAC CGG AAC ACA CTA CAG TAT CCA GCT GAA GCT TCG TAC GC
YPL020c-S2	TCG GTT AAA ATC AAA TGG GCA ATA AAT CTT CTC ATC CTA AGC ATA GGC CAC TAG TGG ATC TG
YPL012w-S1	ATG GAT CAA GAC AAA GTT GCT TTT CTT TTA GAG CTG GAG GCA GCT GAA GCT TCG TAC GC
YPL012w-S2	ATT TGA ACT TTGGAC CTT TCT TAT TAT GTT TGC CAA TCT TGC ATA GGC CAC TAG TGG ATC TG
YPL007c-S1	CCC GTT GTT TGC TCA CGG GAC ATA TCT TTA CAT GCG TTG TCA GCT GAA GCT TCG TAC GC
YPL007c-S2	GGA CTT ATT GGT AGA TAG AAA GGA ATT TGA GGA TTG GAA GGC ATA GGC CAC TAG TGG ATC TG
YPR048w-S1	ATG TCA TCG AGC AAG AAA ATC GTC ATC CTC TAT GGA TCG GCA GCT GAA GCT TCG TAC GC
YPR048w-S2	AAT TAG TTA TTT CCT CAC CTA ATC TCC ATA AGT AGT CTT GGC ATA GGC CAC TAG TGG ATC TG
YPR072w-S1	TGT CTC AAA GAA AGC TAC AAC AGG ATA TCG ATA AGC TTT TCA GCT GAA GCT TCG TAC GC
YPR072w-S2	AGA TTT GCC CAT TCC TGG TGG TAA CTT TTC GAT TTC TTT AGC ATA GGC CAC TAG TGG ATC TG

Gene deletions on chromosome 16	
Name	Sequence 5'-3'
YPR082c-S1	CTT CGA TTG CTG AAA GAG TAA GGA ACT TTG CAG TTA TTT ACA GCT GAA GCT TCG TAC GC
YPR082c-S2	CAA TAA AGT TCA ACT TGT TGT TGT TCC CTG TAC CAA AAT CGC ATA GGC CAC TAG TGG ATC TG
YPR085c-S1	CTG TAC ATT CTT TCG AAA GAC TCC ATG CTG CGA ATT TTT GCA GCT GAA GCT TCG TAC GC
YPR085c-S2	TCC CAC TTT ATA GTT ATG GGA TTT CGA GCT GGA TTC GGT AGC ATA GGC CAC TAG TGG ATC TG
YPR105c-S1	AGC TCG ATC ATC GAG GGC CAA TTG TCT AAA AAT CTA GCA ACA GCT GAA GCT TCG TAC GC
YPR105c-S2	CTG TGT TCT ATC AAT CTT CAT ATT TCT AGC TTT AAT TCT TGC ATA GGC CAC TAG TGG ATC TG
YPR112c-S1	CAT TGT CAA GGG TTT GCC CGT CTA TCT AAC AGA TGA TAA TCA GCT GAA GCT TCG TAC GC
YPR112c-S2	GAA ACC TTC GTT TTC TTC ATC ATC CAC ATC CAG TTT CTT TGC ATA GGC CAC TAG TGG ATC TG
YPR137w-S1	ATG TCA GAT GTT ACC CAA CAG AAA AAG AGG AAA AGA TCC ACA GCT GAA GCT TCG TAC GC
YPR137w-S2	AAA AGC CTG TTT GGT CAA TGA CAG CTG AAT ATA TAC CAT TGC ATA GGC CAC TAG TGG ATC TG
YPR143w-S1	ATG GGC TCC AAG CAC AGA GTA GAC ACT AAG GAT AAG AAA ACA GCT GAA GCT TCG TAC GC
YPR143w-S2	TTC ATT GTC GCT TCC TGC GGC AGC TTT AAC TAA ATC CAA AGC ATA GGC CAC TAG TGG ATC TG
YPR144c-S1	TTC CAG AAA ATG TTA CTC AAT TGG AAG AAG ATG AGA CAG ACA GCT GAA GCT TCG TAC GC
YPR144c-S2	CCA TGC TAC CCC AGG CAA GTA GAC GTT ACC TTG GGA TGA CGC ATA GGC CAC TAG TGG ATC TG
YPR169w-S1	TTT TAC ATC CTG AAC TGC CCA TTA TAA TAA CTG GCT TTG GCA GCT GAA GCT TCG TAC GC
YPR169w-S2	CTT CTT GAT CCC ATG CTC ATA CAG GTC CTT TTT TTT GTT GGC ATA GGC CAC TAG TGG ATC TG

Claims:

1.-A method for the screening of antimycotic substances wherein an essential gene from mycetes or a functionally similar mycete gene, or the corresponding encoded protein, is used as target and wherein the essential gene is selected from the group consisting in

YML114c, YLR186w, YLR215c, YLR222c, YLR243w, YLR272c,
YLR275w, YLR276c, YLR317w, YLR359w, YLR373c, YLR424w,
10 YLR437c, YLR440c, YML023c, YML049c, YML077w, YML093w,
YML127w, YMR032w, YMR093w, YMR131c, YMR185w, YMR212c,
YMR213w, YMR218c, YMR281w, YMR288w, YMR290c, YMR211w,
YMR049c, YMR134w, YDR196c, YDR299w, YDR365c, YDR396w,
YDR407c, YDR416w, YDR449c, YDR472w, YDR499w, YDR141c,
15 YDR324c, YDR325w, YDR398w, YDR246w, YDR236c, YDR361c,
YDR367w, YDR339c, YDR413c, YDR429c, YDR468c, YDR489w,
YDR527w, YDR288w, YDR201w, YDR434w, YDR181c, YDR531w,
YPL126w, YPL093w, YPL063w, YPL024w, YPL020c, YPL012w,
YPL007c, YPL233w, YPL146c, YIL091c, YIL083c, YIL019w,
20 YIL109c, YIL104c, YFL024c, YFR003c, YFR027w, YFR042w,
YIR010w, YIR015w, YPR048w, YPR072w, YPR082c, YPR085c,
YPR105c, YPR112c, YPR137w, YPR143w, YPR144c and YPR169w.

2.-The method of claim 1 wherein mycete cells which
25 express the essential gene, or a functionally similar mycete gene, to a different level are incubated with the substance to be tested and the growth inhibiting effect of the substance is determined.

30 3.-The method of claim 1 wherein said target gene or the corresponding target encoded protein is contacted in vitro with the substance to be tested and the effect of the substance on the target is determined.

35 4.-The method according to any one of claims 1-3 wherein the screened substances partially or totally inhibit the functional expression of the essential genes or the functional activity of the encoded proteins.

5.-The method according to any one of claims 1-4 wherein the mycete species are selected from the group comprising Basidiomycetes, Ascomycetes and Hyphomycetes.

6.- The method according to any one of claims 1-5, wherein said functionally similar genes are essential genes from *Candida* Spp, or *Aspergillus* Spp.

7.- The method according to claim 6, wherein said functionally similar genes are essential genes from *Candida albicans*, or *Aspergillus fumigatus*.

8.- The method according to any one of claims 1 to 7 wherein the functionally similar genes are identified by:

a)providing a *S.cerevisiae* mutant strain in which the gene of *S.cerevisiae* to be investigated is either integrative or extrachromosomal under the control of a regulated promoter,

b)culturing said mutant strain under growth conditions in which the regulated promoter is active,

c)transforming the mutant strain with cDNA or genomic DNA that has been prepared from the mycete-species to investigate and that has been integrated into an appropriate vector,

d)altering the culture condition, so that the regulated promoter is switched off and only *S.cerevisiae* cells which contain a functionally similar gene can survive,

e)isolating and analyzing the cDNA or genomic DNA.

9.- The method according to claim 8 wherein the functionally similar gene has a sequence identity, at the nucleotide level, with the corresponding *S.cerevisiae* essential gene of at least 50%, preferably of at least 60%, and most preferably of at least 70%.

10.- The method according to claim 8 wherein the functionally similar gene encodes a protein having a sequence identity, at the amino-acid level, with the

corresponding *S.cerevisiae* essential gene encoded protein of at least 40%, preferably of at least 50%, more preferably of at least 60% and most preferably of at least 70%.

11.- The method according to any one of claims 1-10 wherein said mycete cells are haploid *S.cerevisiae* cells.

12.- The method according to any one of claims 1-4 or 11 wherein the essential genes of *S.cerevisiae* are identified by integration through homologous recombination of a selection marker at the locus of the gene to be studied.

SEQUENCE LISTING

<110> HOECHST MARION ROUSSEL

<120> METHOD FOR SCREENING ANTIMYCOTIC SUBSTANCES USING
ESSENTIAL GENES FROM S.CEREVISIAE

<130> 16363PC RUU 7

<140>
<141>

<150> 98402254.1
<151> 1998-09-11

<150> 98401007.4
<151> 1998-04-24

<160> 180

<170> PatentIn Ver. 2.1

<210> 1
<211> 59

<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer
YLR243w-S1

<400> 1
atgtctcgcg ttggtgtcat ggtattagga cctgcagggtg cagctgaagc ttcgtacgc 59

<210> 2
<211> 59
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer
YLR272c-S1

<400> 2
tttgggtctc gcactttctc agtctttccaa ctaattttctc cagctgaagc ttcgtacgc 59

<210> 3
<211> 59
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer
YLR275w-S1

<400> 3
ccgtttttatc atgtcgtatg ttgtatctta accattttta cagctgaagc ttcgtacgc 59

<210> 4
<211> 62
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer
YLR275w-S2

10 <400> 4
caacgataac tgaatcacct cctaagaata gtttacttat gcataggcca ctagtggatc 60
tg 62

<210> 5
15 <211> 59
<212> DNA
<213> Artificial Sequence

<220>
20 <223> Description of Artificial Sequence: primer
YLR276c-S1

<400> 5
25 cttcaacggg tctactttac cattcttttg cttactgact cagctgaagc ttcgtaagc 59

<210> 6
<211> 62
<212> DNA
30 <213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer
YLR276c-S2

35 <400> 6
agctatgaga aaaagtctgt ggaaggcgct tatattgacg gcataggcca ctagtggatc 60
tg 62

<210> 7
40 <211> 59
<212> DNA
<213> Artificial Sequence

<220>
45 <223> Description of Artificial Sequence: primer
YLR317w-S1

<400> 7
50 ctgccatctt ctgccaccac ttgtctcttc tttcttgatg cagctgaagc ttcgtaagc 59

<210> 8
<211> 59
<212> DNA
55 <213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer
YLR359w-S1

<400> 8
ggctattgct gagaaggaat tgggcttaac tgttggttaca cagctgaagc ttcgtacgc 59

<210> 9
<211> 62
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer
YLR359w-S2

<400> 9
aacttgactt gttcatcggt taggtacttt tggaaagggt gcataggcca ctagtggatc 60
tg 62

<210> 10
<211> 59
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer
YLR373c-S1

<400> 10
acacacaggt acagagtgct gaaagaggat tgggtgttgcc cagctgaagc ttcgtacgc 59

<210> 11
<211> 62
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer
YLR373c-S2

<400> 11
caaacagact ttgttccttt gtatgtccta tggaagatac gcataggcca ctagtggatc 60
tg 62

<210> 12
<211> 59
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer
YLR424w-S1

<400> 12
gacatgacat acactaatga tgccctgaaa actagtagcg cagctgaagc ttcgtacgc 59

<210> 13
<211> 62
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer
YLR424w-S2

<400> 13
ataggtacttt tctagaggtc aagggcccat aaataaattg gcataggcca ctagtggatc 60
tg 62

<210> 14
<211> 59
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer
YLR437c-S1

<400> 14
attgtgcaag tctgttaaag tcttctcttg gatccattaa cagctgaagc ttcgtacgc 59

<210> 15
<211> 62
<212> DNA

<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer
YLR437c-S2

<400> 15
catcacacac taatacagga acaaacaaga cttaatggac gcataggcca ctagtggatc 60
tg 62

<210> 16
<211> 59
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer
YLR440c-S1

<400> 16
ttgccaaagaa aattgcagta aaaatggttg aagagcaact cagctgaagc ttcgtacgc 59

<210> 17
<211> 62
<212> DNA

<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer
YLR440c-S2

<400> 17
gtcccaattc tagtgtgctc cattgcgatg taacaatttc gcataggcca ctagtggatc 60
tg 62

<210> 18
<211> 59
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer
YFL024c-S1

<400> 18
tgatgaattt ttctgggtta tagaagagtt ctgtttcgct cagctgaagc ttcgtacgc 59

<210> 19
<211> 62
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer
YML049c-S2

<400> 19
actcctgcat cggacacttc gtcgatctgg aagcagggtc gcataggcca ctagtggatc 60
tg 62

<210> 20
<211> 62
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer
YFL024c-S2

<400> 20
acaccttcaa acgctataga gatcaatgac ggttcgcata gcataggcca ctagtggatc 60
tg 62

<210> 21
<211> 59
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer
YFR003c-S1

<400> 21
tgtggaagag gttcccgag ttttgcagct tcgagcaact cagctgaagc ttcgtacgc 59

<210> 22
<211> 62
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer
YFR003c-S2

<400> 22

5 atcttcttttg tctacgttcg ttaaagtcaa gatccttctc gcataggcca ctagtggatc 60
tg 62

<210> 23

<211> 59

10 <212> DNA

<213> Artificial Sequence

<220>

15 <223> Description of Artificial Sequence: primer
YFR027w-S1

<400> 23

aatgaaagct aggaaatcgc agagaaaagc gggcagtaaa cagctgaagc ttcgtacgc 59

20 <210> 24

<211> 62

<212> DNA

<213> Artificial Sequence

25 <220>

<223> Description of Artificial Sequence: primer
YFR027w-S2

<400> 24

30 aatttggttg cgatacccaa cttccttgct gtcctgcaca gcataggcca ctagtggatc 60
tg 62

<210> 25

<211> 59

35 <212> DNA

<213> Artificial Sequence

<220>

40 <223> Description of Artificial Sequence: primer
YFR042w-S1

<400> 25

agtttgcacc aatggcaata tgctgtgat aaagataagg cagctgaagc ttcgtacgc 59

45 <210> 26

<211> 62

<212> DNA

<213> Artificial Sequence

50 <220>

<223> Description of Artificial Sequence: primer
YFR042w-S2

<400> 26

55 catggaagtt atttggttgc ttagattcca cgggttcaaa gcataggcca ctagtggatc 60
tg 62

<210> 27

<211> 59
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer
YIL109c-S1

<400> 27
tgtctcatca caagaaacgt gtttaccac aagctcagct cagctgaagc ttcgtacgc 59

<210> 28
<211> 59
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer
YML077w-S1

<400> 28
atgggggat attcattttg gatctttgat aggcattgta cagctgaagc ttcgtacgc 59

<210> 29
<211> 62
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer
YIL109c-S2

<400> 29
tcatgatttg taagaattct ctgtaacttt cgttattcaa gcataggcca ctagtggatc 60
tg 62

<210> 30
<211> 59
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer
YIL091c-S1

<400> 30
agtgcagtt ctgtgaggga aaagaatgat aatttccgtg cagctgaagc ttcgtacgc 59

<210> 31
<211> 62
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer
YIL091c-S2

<400> 31

cattgtaaaa ttcaggattg ttgggagget tataaaaaaac gcataggcca ctagtggatc 60
tg 62

<210> 32

<211> 59

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer
YIL083c-S1

<400> 32

acctctaccc gtgctcaaca gacctcaaat tcatacgtct cagctgaagc ttcgtacgc 59

<210> 33

<211> 62

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer
YIL083c-S2

<400> 33

cgatgacttc tgggattatc atctcttcaa tgatatggtg gcataggcca ctagtggatc 60
tg 62

<210> 34

<211> 59

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer
YIL019w-S1

<400> 34

ttcaaagaaa agcttttgaa agtcagttcg gatctttaga cagctgaagc ttcgtacgc 59

<210> 35

<211> 62

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer
YIL019w-S2

<400> 35

tagcgacggg atttcttttt gccattaaat ttaccactcc gcataggcca ctagtggatc 60
tg 62

<210> 36

<211> 59

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer
YIL104c-S1

<400> 36

cccccttact atttaagatt aagatttcct cacgaattaa cagctgaagc ttcgtacgc 59

<210> 37

<211> 62

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer
YIL104c-S2

<400> 37

cctgatacct gtaatgattg caatcttgat gagagagctg gcataggcca ctagtggatc 60
tg 62

<210> 38

<211> 59

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer
YIR010w-S1

<400> 38

atgagtctgg aaccacaca aacggtctcc ggtacgccgc cagctgaagc ttcgtacgc 59

<210> 39

<211> 62

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer
YML077w-S2

<400> 39

ttctattggt gatctttctt gtcccttgac ctctcatttc gcataggcca ctagtggatc 60
tg 62

<210> 40

<211> 62

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer
YIR010w-S2

<400> 40

accttagctc atcgactttt gtttctaact ttgtctcaac gcataggcca ctagtggatc 60
tg 62

<210> 41
<211> 59
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer
YIR015w-S1

<400> 41
gcgaaccagg accatttcca tagattaaac tacctctacc cagctgaagc ttctgtacgc 59

<210> 42
<211> 62
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer
YIR015w-S2

<400> 42
atttcagtt tttttggggc ccataacaac cgatggcatt gcataggcca ctagtggatc 60
tg 62

<210> 43
<211> 59
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer
YPL233w-S1

<400> 43
atgtcacaag gtcagtccaa aaaactggac gtaactgttg cagctgaagc ttctgtacgc 59

<210> 44
<211> 62
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer
YPL233w-S2

<400> 44
caatcctcct ccaggaagtc cattaagcgc ttgacctttt gcataggcca ctagtggatc 60
tg 62

<210> 45
<211> 59
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

YPL146c-S1

<400> 45
tccaactaat ctaaccaaga aaccatctca atacaaacag cagctgaagc ttcgtacgc 59

<210> 46
<211> 62
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer
YPL146c-S2

<400> 46
tttgaagtcc ttatgtgtcc acttttcagt gattttctgc gcataggcca ctagtggatc 60
tg 62

<210> 47
<211> 59
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer
YPL126w-S1

<400> 47
atgacgcaat ccctaggtat cgaacagtat aaactgtcag cagctgaagc ttcgtacgc 59

<210> 48
<211> 62
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer
YPL126w-S2

<400> 48
tatgttaata ctttcatcac acgatcaaaa aatgtatcca gcataggcca ctagtggatc 60
tg 62

<210> 49
<211> 59
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer
YPL093w-S1

<400> 49
caagattaca agaattcagag cgttctatat gcgtaaagtt cagctgaagc ttcgtacgc 59

<210> 50
<211> 59
<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer
YML093w-S1

<400> 50

gctaacttaa atatggcaaa aaagaaatct aagagcagat cagctgaagc ttcgtacgc 59

<210> 51

<211> 62

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer
YPL093w-S2

<400> 51

gggaaatctg tcttaccgac accacgctta cactgaata gcataggcca ctagtggatc 60
tg 62

<210> 52

<211> 59

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer
YPL063w-S1

<400> 52

ttcaagcatc cagaagactt ttaacaagtt attcaagttt cagctgaagc ttcgtacgc 59

<210> 53

<211> 62

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer
YPL063w-S2

<400> 53

ggattcagca atctttcttct ttttcttttc ctcttcaaatt gcataggcca ctagtggatc 60
tg 62

<210> 54

<211> 59

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer
YPL024w-S1

<400> 54

atgtcttttt catctatctt atcacaggat atcacagatg cagctgaagc ttcgtacgc 59

<210> 55
<211> 62
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer
YPL024w-S2

10

<400> 55
acttgtgagt ccttcaatat gaaaacgccc ctattgaaca gcataggcca ctagtggatc 60
tg 62

15

<210> 56
<211> 59
<212> DNA
<213> Artificial Sequence

20

<220>
<223> Description of Artificial Sequence: primer
YPL020c-S1

25

<400> 56
tcagttgaag tagataagca ccggaacaca ctacagtatc cagctgaagc ttcgtaagc 59

30

<210> 57
<211> 62
<212> DNA
<213> Artificial Sequence

35

<220>
<223> Description of Artificial Sequence: primer
YPL020c-S2

40

<400> 57
tcgggttaaaa tcaaattggc aataaatctt ctcatcctaa gcataggcca ctagtggatc 60
tg 62

45

<210> 58
<211> 59
<212> DNA
<213> Artificial Sequence

50

<220>
<223> Description of Artificial Sequence: primer
YPL012w-S1

55

<400> 58
atggatcaag acaaagttgc tttctttta gagctggagg cagctgaagc ttcgtaagc 59

<210> 59
<211> 62
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

YPL012w-S2

<400> 59

atttgaactt tggacctttc ttattatggt tgccaatctt gcataggcca ctagtggatc 60
tg 62

<210> 60

<211> 59

<212> DNA

10 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer
YPL007c-S1

15

<400> 60

cccgttggtt gctcacggga catatcttta catgcgttgt cagctgaagc ttcgtacgc 59

20

<210> 61

<211> 62

<212> DNA

<213> Artificial Sequence

25

<220>

<223> Description of Artificial Sequence: primer
YML093w-S2

30

<400> 61

caaaggatca ataacttggc ctggcttagt catgattctc gcataggcca ctagtggatc 60
tg 62

<210> 62

<211> 62

35

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer
YPL007c-S2

40

<400> 62

ggacttattg gtagatagaa aggaatttga ggattggaag gcataggcca ctagtggatc 60
tg 62

45

<210> 63

<211> 59

<212> DNA

<213> Artificial Sequence

50

<220>

<223> Description of Artificial Sequence: primer
YPR048w-S1

55

<400> 63

atgtcatcga gcaagaaaat cgtcatcttc tatggatcgg cagctgaagc ttcgtacgc 59

<210> 64

<211> 62
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer
YPR048w-S2

<400> 64
aattagttat ttcctcacct aatctccata agtagtcttg gcataggcca ctagtggatc 60
tg 62

<210> 65
<211> 59
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer
YPR072w-S1

<400> 65
tgtctcaaag aaagctacaa caggatatcg ataagctttt cagctgaagc ttcgtacgc 59

<210> 66
<211> 62
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer
YPR072w-S2

<400> 66
agatttgccc attcctggtg gtaacttttc gatttcttta gcataggcca ctagtggatc 60
tg 62

<210> 67
<211> 59
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer
YPR082c-S1

<400> 67
cttcgattgc tgaaagagta aggaactttg cagttattta cagctgaagc ttcgtacgc 59

<210> 68
<211> 62
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer
YPR082c-S2

<400> 68
caataaaagtt caacttggtt ttgttccctg taccaaaaatc gcataggcca ctagtggatc 60
tg 62

<210> 69
<211> 59
<212> DNA
<213> Artificial Sequence

10 <220>
<223> Description of Artificial Sequence: primer
YPR085c-S1

11 <400> 69
ctgtacattc ttctgaaaga ctccatgctg cgaatttttg cagctgaagc ttctgtacgc 59

<210> 70
<211> 62
<212> DNA
20 <213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer
YPR085c-S2

25 <400> 70
tcccacttta tagttatggg atttcgagct ggattcggta gcataggcca ctagtggatc 60
tg 62

30 <210> 71
<211> 59
<212> DNA
<213> Artificial Sequence

35 <220>
<223> Description of Artificial Sequence: primer
YML114c-S1

40 <400> 71
aacgtgtaat tgagggactc ataaagggca atgacttcca cagctgaagc ttctgtacgc 59

<210> 72
<211> 59
<212> DNA
45 <213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer
YPR105c-S1

50 <400> 72
agctcgatca tctagggccca attgtctaaa aatctagcaa cagctgaagc ttctgtacgc 59

55 <210> 73
<211> 62
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer
YPR105c-S2

<400> 73

ctgtgttcta tcaatcttca tatttctaga tttaattctt gcataggcca ctagtggatc 60
tg 62

<210> 74

<211> 59

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer
YPR112c-S1

<400> 74

cattgtcaag ggtttgcccg tctatctaac agatgataat cagctgaagc ttcgtacgc 59

<210> 75

<211> 59

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer
YPR137c-S1

<400> 75

atgtcagatg ttacccaaca gaaaaagagg aaaagatcca cagctgaagc ttcgtacgc 59

<210> 76

<211> 62

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer
YPR112c-S2

<400> 76

gaaaccttcg ttttcttcat catccacatc cagtttcttt gcataggcca ctagtggatc 60
tg 62

<210> 77

<211> 59

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer
YPR143w-S1

<400> 77

atgggctcca agcacagagt agacactaag gataagaaaa cagctgaagc ttcgtacgc 59

<210> 78

<211> 62
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer
 YPR143w-S2

<400> 78
 10 ttcattgtcg cttcctgagg cagctttaac taaatccaaa gcataggcca ctagtggatc 60
 tg 62

<210> 79
 <211> 59
 15 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer
 20 YPR144c-S1

<400> 79
 ttcagaaaa tggtactcaa ttggaagaag atgagacaga cagctgaagc ttcgtacgc 59

25 <210> 80
 <211> 62
 <212> DNA
 <213> Artificial Sequence

30 <220>
 <223> Description of Artificial Sequence: primer
 YPR144c-S2

<400> 80
 35 ccattgctacc ccaggcaagt agacgttacc ttgggatgac gcataggcca ctagtggatc 60
 tg 62

40 <210> 81
 <211> 62
 <212> DNA
 <213> Artificial Sequence

<220>
 45 <223> Description of Artificial Sequence: primer
 YML114c-S2

<400> 81
 50 gacttgtagt agcatcgata ttggttgtgt tatgtgctac gcataggcca ctagtggatc 60
 tg 62

<210> 82
 <211> 59
 <212> DNA
 55 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer

YPR169w-S1

<400> 82
ttttacatcc tgaactgccc attataataa ctggctttgg cagctgaagc ttcgtacgc 59

<210> 83
<211> 62
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer
YPR169w-S2

<400> 83
cttcttgatc ccattgctcat acaggctcctt ttttttggtg gcattaggcca ctattggatc 60
tg 62

<210> 84
<211> 59
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer
YML127w-S1

<400> 84
ccgctaaatg gtactccagt aagcgaggca cccgccacaa cagctgaagc ttcgtacgc 59

<210> 85
<211> 62
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer
YML127w-S2

<400> 85
ataaccccga cgtgttttcc atgtattcag acaatgctaa gcattaggcca ctattggatc 60
tg 62

<210> 86
<211> 59
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer
YMR032w-S1

<400> 86
ctacagttat gaagcttggt tttgggaccc aaacgacaat cagctgaagc ttcgtacgc 59

<210> 87
<211> 62
<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer
YMR032w-S2

<400> 87

<210> 88

<211> 59

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer
YMR093w-S1

<400> 88

<210> 89

<211> 62

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer
YMR093w-S2

<400> 89

<210> 90

<211> 59

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer
YMR131c-S1

<400> 90

<210> 91

<211> 62

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer
YMR131c-S2

<400> 91

<210> 92

<211> 59

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer
YMR185w-S1

<400> 92

atcaacatac acgatatatt gaatacaaga ccgaagctca cagctgaagc ttcgtacgc 59

<210> 93

<211> 62

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer
YMR185w-S2

<400> 93

gtaatggggtt ataaactatc tagtacgggtt aaaagcttgt gcataggcca ctagtggatc 60
tg 62

<210> 94

<211> 59

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer
YMR212c-S1

<400> 94

cctcttgaac ttaaagaatg taaatcttca ttgctgtctt cagctgaagc ttcgtacgc 59

<210> 95

<211> 59

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer
YDR499w-S1

<400> 95

<210> 96

<211> 62

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer
YMR212c-S2

<400> 96

cggatgatgt tcacaccaaa acatcagaaa ctggtcaatc gcataggcca ctagtggatc 60
tg 62

<210> 97

<211> 59

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer
YMR213w-S1

<400> 97

atacgtgaaa ggcgggtgtat ggaccaatgt ggaggatcag cagctgaagc ttcgtacgc 59

<210> 98

<211> 62

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer
YMR213w-S2

<400> 98

gctgtaactg ttcaatagac tccacttttg attggatcga gcataggcca ctagtggatc 60
tg 62

<210> 99

<211> 59

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer
YMR218c-S1

<400> 99

gactcaaagt cattagagt atcaactcta caacttttac cagctgaagc ttcgtacgc 59

<210> 100

<211> 62

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer
YMR218c-S2

<400> 100

gaaggcattt gacggaactg tacgaacggt taacaggctt gcataggcca ctagtggatc 60
tg 62

<210> 101

<211> 64

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
primeryDR472w-S1

<400> 101

atgtc tcaaagaata attcaaccaa ggcgatctga ccaaccagct gaagcttcgt 60

acgc

64

<210> 102

<211> 62

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

YML023c-S2

<400> 102

attagttact tattctataa ttacactttt atcatgaacg gcataggcca ctagtggatc 60
tg 62

<210> 103

<211> 62

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

YLR222c-S2

<400> 103

aatatgtaac ttgtttcaac taagttatca accottgtga gcataggcca ctagtggatc 60
tg 62

<210> 104

<211> 62

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

YLR243w-S2

<400> 104

gataatatgg ttctataact gtcaggatta ttagattcca gcataggcca ctagtggatc 60
tg 62

<210> 105

<211> 62

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

YLR272c-S2

<400> 105

ggtaactgac ttctttactt tatgagatgt ccggcttttag gcataggcca ctagtggatc 60
tg 62

<210> 106

<211> 59

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer
YML049c-S1

<400> 106

aattcctgct cattcaagga aagtctcagg aaattttcac cagctgaagc ttcgtacgc 59

<210> 107

<211> 62

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer
YLR317w-S2

<400> 107

gaagtaaaact aactagtaaa gtaggctaatt tcgaaacgat gcataggcca ctagtggatc 60
tg 62

<210> 108

<211> 62

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
primerYPR143w-S1

<400> 108

aaaagcctgt ttggtcaatg acagctgaat atataccatt gcataggcca ctagtggatc 60
tg 62

<210> 109

<211> 62

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
primerYDR472w-S2

<400> 109

agccaaatct caaaccttcc ctgtcaagca cttgcctgtc gcataggcca ctagtggatg 60
tg 62

<210> 110

<211> 59

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer
YMR281w-S1

<400> 110

ctgaagaaaa gttaaataaa gatgttgagg cgtacaaagg cagctgaagc ttcgtacgc 59

<210> 111
<211> 62
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
primerYMR281w-S2

<400> 111
agtacgtatt gtgcatgtgt attcataagt gaaagcttgt gcataggcca ctagtggatc 60
tg 62

15 <210> 112
<211> 59
<212> DNA
<213> Artificial Sequence

20 <220>
<223> Description of Artificial Sequence: primer
YMR288w-S1

25 <400> 112
gaaaacctgc agaaagaagc tgcacgtatt ggtgagaacg cagctgaagc ttcgtacgc 59

<210> 113
<211> 62
<212> DNA
30 <213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
primerYMR288w-S2

35 <400> 113
ccaaaccttc taaaatacgc ataatagcat gtggtgaagt gcataggcca ctagtggatc 60
tg 62

40 <210> 114
<211> 59
<212> DNA
<213> Artificial Sequence

45 <220>
<223> Description of Artificial Sequence:
primerYMR290c-S1

50 <400> 114
tgagttttac gtcttttggt atttggcgtt tttccactgg cagctgaagc ttcgtacgc 59

<210> 115
<211> 62
<212> DNA
55 <213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

YDR499w-S2

<400> 115

ggtactttac ttgcattatt ctccccgttc ttttattcaa gcataggcca ctagtggatg 60
tg 62

<210> 116

<211> 62

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer
YMR290c-S2

<400> 116

gataagctga gcaatattaa caggagaagt atggctaccc gcataggcca ctagtggatc 60
tg 62

<210> 117

<211> 59

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer
YMR211w-S1

<400> 117

agagagcaaaa ccatttgact actcaattct tcaatataca cagctgaagc ttcgtacgc 59

<210> 118

<211> 62

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
primerYMR211w-S2

<400> 118

atttcaatca tcttactccg tgaatcaggt tcggaatgat gcataggcca ctagtggatc 60
tg 62

<210> 119

<211> 59

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer
YDR196c-S1

<400> 119

atgcttatga tcaaattgtg ttatacttca aggacaaaat cagctgaagc ttcgtacgc 59

<210> 120

<211> 62

<212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:
 primerYDR196c-S2

<400> 120
 ttccaatctg ttcgtataag tcaaccaatg tgctgttatt gcataggcca ctagtggatc 60
 tg 62

<210> 121
 <211> 59
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer
 YDR299w-S1

<400> 121
 atggaaaaat cactagcgga tcaaatttcc gatatcgcca cagctgaagc ttcgtacgc 59

<210> 122
 <211> 62
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:
 primerYDR299w-S2

<400> 122
 caaagatttg gatatcatcg tttttaacag cctctaattc gcataggcca ctagtggatc 60
 tg 62

<210> 123
 <211> 59
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer
 YDR365c-S1

<400> 123
 ctggagagaa cccaaagaag gaaggtgtag atgctaggtt cagctgaagc ttcgtacgc 59

<210> 124
 <211> 62
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:
 primerYDR365c-S2

<400> 124
ttagtatgct ttttattaac agatttcaac ttgcttttct gcataggcca ctagtggatc 60
tg 62

<210> 125
<211> 59
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer
YDR396w-S1

<400> 125
cagatacact attgtggtgt aatctggacc ttgactgtct cagctgaagc ttcgtacgc 59

<210> 126
<211> 59
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer
YMR049c-S1

<400> 126
cagactattg attactttat gaccgggttag tttcttttagt cagctgaagc ttcgtacgc 59

<210> 127
<211> 62
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer
YDR396w-S2

<400> 127
tagagaaaac actgaatgat cttagcgacc gtacaaaaga gcataggcca ctagtggatc 60
tg 62

<210> 128
<211> 59
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer
YDR407c-S1

<400> 128
ttcttaagca tttcccaagc tatgttggcc catctaagat cagctgaagc ttcgtacgc 59

<210> 129
<211> 62
<212> DNA
<213> Artificial Sequence

2200

2230 Description of Artificial Sequence: primer
YDR407c-S2

4000 129

ataaacagac aagataacgt ttccagagtc gaactggatt gcataggcca ctagtggatc 60
tg 62

2100 130

2110 59

2120 DNA

2130 Artificial Sequence

2200

2230 Description of Artificial Sequence: primer
YDR416w-S1

4000 130

acttacatgg aaaagatata tcgagtattg gaaagaggag cagctgaagc ttcgtacgc 59

2100 131

2110 62

2120 DNA

2130 Artificial Sequence

2200

2230 Description of Artificial Sequence:
primerYDR416w-S2

4000 131

tcaaatatct agttctatct catctggatt aatcgaatat gcataggcca ctagtggatc 60
tg 62

2100 132

2110 59

2120 DNA

2130 Artificial Sequence

2200

2230 Description of Artificial Sequence: primer
YDR449c-S1

4000 132

cacatcaccg atttctaata atgtcgaaga caagatacta cagctgaagc ttcgtacgc 59

2100 133

2110 62

2120 DNA

2130 Artificial Sequence

2200

2230 Description of Artificial Sequence: primer
YDR449c-S2

4000 133

ataattaaat ctagaatttt atacctagga tcattctctg gcataggcca ctagtggatc 60
tg 62

<210> 134
<211> 59
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer
YDR141c-S1

<400> 134
ttcgtaatct ttgaattctg cgatttcacg taccagcgcg cagctgaagc ttcgtacgc 59

<210> 135
<211> 62
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
primerYDR141c-S2

<400> 135
cactaaagcc ccttacaatt gactcaaata ataaacaact gcataggcca ctagtggatc 60
tg 62

<210> 136
<211> 59
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer
YDR324c-S1

<400> 136
aagaagcctg aaaatacgaa acaaaccggt gaagatgacc cagctgaagc ttcgtacgc 59

<210> 137
<211> 62
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
primerYMR049c-S2

<400> 137
tctgtttctaa cataactagg tcaatgatgg ctaagaacaa gcataggcca ctagtggatc 60
tg 62

<210> 138
<211> 62
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer
YDR324c-S2

<400> 138
 aaacactaac ttggttgaa taaacgcctt ttgtttggag gcataggcca ctagtggatc 60
 tg 62

<210> 139
 <211> 59
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:
 primerYDR325w-S1

<400> 139
 gacattaata cgaaaatctt taactcagtt gctgaagtat cagctgaagc ttctgacgc 59

<210> 140
 <211> 62
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:
 primerYDR325w-S2

<400> 140
 acctcgctga aagactctga atccttatct tcttcatcta gcataggcca ctagtggatc 60
 tg 62

<210> 141
 <211> 59
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer
 YDR398w-S1

<400> 141
 atggattctc ctgttctaca gtccgcttat gacccatcag cagctgaagc ttctgacgc 59

<210> 142
 <211> 62
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer
 YDR398w-S2

<400> 142
 aacgtcacta tatccggtt cctcctcgcc gtcgctctgc gcataggcca ctagtggatc 60
 tg 62

<210> 143
 <211> 59

<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer
YDR246w-S1

<400> 143

atggccatcg aaacaatact tgtaataaac aaatcaggcg cagctgaagc ttcgtacgc 59

<210> 144

<211> 62

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer
YDR246w-S2

<400> 144

aacagggttag atcttatagg catttccatt gagtaagatg gcataggcca ctagtggatc 60
tg 62

<210> 145

<211> 59

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
primerYDR236c-S1

<400> 145

ctaaaatatt gaacttgacc ctggcccat aaaaatcatt cagctgaagc ttcgtacgc 59

<210> 146

<211> 62

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer
YDR236c-S2

<400> 146

ttgaagtgtt gatgtttacg tggactatct atgtttcggt gcataggcca ctagtggatc 60
tg 62

<210> 147

<211> 62

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
primerYDR361c-S2

<400> 147

ttaccaagtg gaaattttctg ttccaatc atcgatacct gcataggcca ctagtggatc 60
tg 62

<210> 148

<211> 59

<212> DNA

<213> Artificial Sequence

<220>

10 <223> Description of Artificial Sequence: primer
YMR134w-S1

<400> 148

gcaaagtgtg gtatagaaaa agaaccaaag gccggtatgt cagctgaagc ttcgtacgc 59

<210> 149

<211> 59

<212> DNA

<213> Artificial Sequence

<220>

20 <223> Description of Artificial Sequence: primer
YDR361c-S1

<400> 149

ggttcaagct atcaaattaa atgatttaaa aaataggaag cagctgaagc ttcgtacgc 59

<210> 150

<211> 59

<212> DNA

30 <213> Artificial Sequence

<220>

35 <223> Description of Artificial Sequence: primer
YDR367w-S1

<400> 150

atctgcgtac ttatataaat cgataccatt tccacttggt cagctgaagc ttcgtacgc 59

<210> 151

<211> 62

<212> DNA

40 <213> Artificial Sequence

<220>

45 <223> Description of Artificial Sequence: primer
YDR367w-S2

<400> 151

50 gttttgttct acgtcatccc tatcaactaa atatttgggg gcataggcca ctagtggatc 60
tg 62

<210> 152

<211> 59

<212> DNA

55 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
primerYDR339c-S1

<400> 152

5 tatggggtaaa gctaagaaaa caagaaagtt tggcctcgta cagctgaagc ttcgtacgc 59

<210> 153

<211> 62

<212> DNA

10 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer
YDR339c-S2

15

<400> 153

taaaagacat ctggcaattt ttcaatgacg tatgcgtgac gcataggcca ctagtggatc 60
tg 62

20

<210> 154

<211> 59

<212> DNA

<213> Artificial Sequence

25

<220>

<223> Description of Artificial Sequence: primer
YDR413c-S1

<400> 154

30 ttcttttggtt tattcttcgt tcatttttgg tcaaatatct cagctgaagc ttcgtacgc 59

<210> 155

<211> 62

<212> DNA

35 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer
YDR413c-S2

40

<400> 155

acaaaagaaa gcacaagagt ttattaagga gcaggaaagg gcataggcca ctagtggatc 60
tg 62

45

<210> 156

<211> 59

<212> DNA

<213> Artificial Sequence

50

<220>

<223> Description of Artificial Sequence: primer
YDR429c-S1

<400> 156

55 tctagatcta tcattacata caagattgaa gacggtgtca cagctgaagc ttcgtacgc 59

<210> 157

<211> 62

<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer
YDR429c-S2

<400> 157

tttctttgtt tctaacgaca gaaactcttg gaatgggtgc gcataggcca ctagtggatc 60
tg 62

<210> 158

<211> 59

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
primerYDR468c-S1

<400> 158

gtcacataac tgctgggtgat gacgatcaag aggaggaaat cagctgaagc ttcgtacgc 59

<210> 159

<211> 62

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
primerYMR134w-S2

<400> 159

tgtgtgtgtg cctacctgca tgtatgcatt tagcaattga gcataggcca ctagtggatc 60
tg 62

<210> 160

<211> 62

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer
YDR468c-S2

<400> 160

caagaacgaca ataagaagtc ctatacaaca atcgtcgtat gcataggcca ctagtggatc 60
tg 62

<210> 161

<211> 59

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer
YDR489w-S1

<400> 161
actaccacaca gagatgcaaa tacaatagtg ggttcgtcct cagctgaagc ttcgtacgc 59

5 <210> 162
<211> 62
<212> DNA
<213> Artificial Sequence

10 <220>
<223> Description of Artificial Sequence: primer
YDR489w-S2

15 <400> 162
agtcgggctc atctatcatg tttagctac ctctgtatc gcataggcca ctagtggatc 60
tg 62

20 <210> 163
<211> 59
<212> DNA
<213> Artificial Sequence

25 <220>
<223> Description of Artificial Sequence: primer
YDR527w-S1

30 <400> 163
atggacttac tggcgatat agtggagaaa gatacatctg cagctgaagc ttcgtacgc 59

35 <210> 164
<211> 62
<212> DNA
<213> Artificial Sequence

40 <220>
<223> Description of Artificial Sequence: primer
YDR527w-S2

45 <400> 164
ccccaccgcc ttgtttccat aaccaaagtg catcaatagc gcataggcca ctagtggatc 60
tg 62

50 <210> 165
<211> 59
<212> DNA
<213> Artificial Sequence

55 <220>
<223> Description of Artificial Sequence: primer
YDR288w-S1

60 <400> 165
atgagttcta tagataatga cagcgatgtg gatttaacag cagctgaagc ttcgtacgc 59

65 <210> 166
<211> 62
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer
YDR288w-S2

<400> 166

gcccatgatt tcttgacacca atttttcaag agactctagt gcataggcca ctagtggatc 60
tg 62

<210> 167

<211> 59

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer
YDR201w-S1

<400> 167

cccattgtctg gactattcag agcatcatcg tcattccatac cagctgaagc ttctgtacgc 59

<210> 168

<211> 62

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer
YDR201w-S2

<400> 168

aaaagggttt tccgttttagt tcccgaatat gatgttgaaa gcataggcca ctagtggatc 60
tg 62

<210> 169

<211> 59

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
primerYDR434w-S1

<400> 169

atgtccaatg caaatctaag aaaatgggtt ggtttttctg cagctgaagc ttctgtacgc 59

<210> 170

<211> 59

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer
YML023c-S1

<400> 170

cacgcaatgg tgcacattat ttgttggaac tcaactgagaa cagctgaagc ttctgtacgc 59

<210> 171
<211> 62
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer
YDR434w-S2

10 <400> 171
taaaggtaaa tacacagcta tcatgtgctc ttgtgggaag gcataggcca ctagtggatc 60
tg 62

15 <210> 172
<211> 59
<212> DNA
<213> Artificial Sequence

20 <220>
<223> Description of Artificial Sequence: primer
YDR181c-S1

25 <400> 172
aggataaacc caaatgctgg acatctaagg aaatctaagt cagctgaagc ttcgtacgc 59

30 <210> 173
<211> 62
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer
YDR181c-S2

35 <400> 173
tagttgggtt tgaatcgta tcacgggaga acattgcttt gcataggcca ctagtggatc 60
tg 62

40 <210> 174
<211> 59
<212> DNA
<213> Artificial Sequence

45 <220>
<223> Description of Artificial Sequence: primer
YDR531w-S1

50 <400> 174
atgccgcgaa ttactcaaga gatattcttac aattgcgatt cagctgaagc ttcgtacgc 59

<210> 175
<211> 62
<212> DNA
<213> Artificial Sequence

55 <220>
<223> Description of Artificial Sequence:
primerYDR531w-S2

<400> 175
aaataagcta ttgcccgaat attgttggag atggcgaata gcataggcca ctagtggatc 60
tg 62

<210> 176
<211> 59
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
primerYLR186w-S1

<400> 176
ctagtcacca agaagaaaac ccgtaaaatc gtaggtcatg cagctgaagc ttcgtacgc 59

<210> 177
<211> 62
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer
YLR186w-S2

<400> 177
atacaaagag gatgccaaagt agacttaaac actataaaat gcataggcca ctagtggatc 60
tg 62

<210> 178
<211> 59
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
primerYLR215c-S1

<400> 178
ttacttattg atgtctctac aagaatatac aacttttata cagctgaagc ttcgtacgc 59

<210> 179
<211> 62
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
primerYLR215c-S2

<400> 179
agctctcgga ttgcttcagg atttaaacta gcttctacga gcataggcca ctagtggatc 60
tg 62

<210> 180
<211> 59
<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
primerYLR222c-S1

<400> 180

ctctcaacgg tagtaagcca tactacgtac aatatggatc cagctgaagc ttcgtacgc 59